<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711416804</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711416804</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Diabetes and Insulin Resistance</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Role of Hyperbaric Oxygen in the Treatment of Diabetic Foot Ulcers</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Tiaka</surname>
<given-names>Elisavet K.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711416804">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Papanas</surname>
<given-names>Nikolaos</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711416804">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319711416804"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Manolakis</surname>
<given-names>Anastassios C.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0003319711416804">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maltezos</surname>
<given-names>Efstratios</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0003319711416804">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711416804"><label>1</label>Outpatient Clinic of the Diabetic Foot, Second Department of Internal Medicine, Democritus University of Thrace, Greece</aff>
<aff id="aff2-0003319711416804"><label>2</label>Department of Internal Medicine-Gastroenterology, University of Thessaly, School of Medicine, Larissa, Greece</aff>
<author-notes>
<corresp id="corresp1-0003319711416804">Nikolaos Papanas, Outpatient Clinic of the Diabetic Foot, Second Department of Internal Medicine, Democritus University of Thrace, G. Kondyli 22, Alexandroupolis, 68100, Greece Email: <email>papanasnikos@yahoo.gr</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>63</volume>
<issue>4</issue>
<fpage>302</fpage>
<lpage>314</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Diabetic foot ulcers are still extremely difficult to heal. Therefore, therapeutic options to improve healing rates are continuously being explored. Hyperbaric oxygen (HBO) has been used in addition to standard treatment of the diabetic foot for more than 20 years. Evidence suggests that HBO reduces amputation rates and increases the likelihood of healing in infected diabetic foot ulcers, in association with improved tissue oxygenation, resulting in better quality of life. Nonetheless, HBO represents an expensive modality, which is only available in few centers. Moreover, adverse events necessitate a closer investigation of its safety. Finally, it is not entirely clear which patients stand to benefit from HBO and how these should be selected. In conclusion, HBO appears promising, but more experience is needed before its broad implementation in the routine care of the diabetic foot.</p>
</abstract>
<kwd-group>
<kwd>diabetic foot</kwd>
<kwd>chronic ulcers</kwd>
<kwd>hyperbaric oxygen treatment</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319711416804">
<title>Introduction</title>
<sec id="section2-0003319711416804">
<title>Diabetic Foot</title>
<p>Diabetic foot ulceration is a full-thickness penetration of the foot dermis in patients with diabetes mellitus.<sup><xref ref-type="bibr" rid="bibr1-0003319711416804">1</xref><xref ref-type="bibr" rid="bibr2-0003319711416804"/><xref ref-type="bibr" rid="bibr3-0003319711416804"/>–<xref ref-type="bibr" rid="bibr4-0003319711416804">4</xref></sup> It represents a major cause of morbidity worldwide, given that the annual incidence of ulceration and amputation is as high as 2.5% to 10.7% and 0.25% to 1.8%, respectively.<sup><xref ref-type="bibr" rid="bibr1-0003319711416804">1</xref><xref ref-type="bibr" rid="bibr2-0003319711416804"/><xref ref-type="bibr" rid="bibr3-0003319711416804"/>–<xref ref-type="bibr" rid="bibr4-0003319711416804">4</xref></sup> Diabetic foot ulcers have a multifactorial etiology, in which neuropathy, ischemia, and infection are important. First, peripheral neuropathy leads to stocking-distribution loss of protective sensation and foot deformity. Thus, plantar pressures are redistributed, and some foot areas sustain chronic high pressure, which ultimately result in ulceration. This is aggravated by autonomic neuropathy, which is responsible for callus formation and dry, hyperkeratotic skin, susceptible to cracking. The latter creates gates of entry for bacteria, leading to potential deep-tissue infection.<sup><xref ref-type="bibr" rid="bibr5-0003319711416804">5</xref>,<xref ref-type="bibr" rid="bibr6-0003319711416804">6</xref></sup> Second, wound healing may also be impaired in cases with concomitant lower extremity ischemia due to peripheral arterial disease. Last but not least, diabetic patients are susceptible to infection, mainly due to impaired cellular and humoral immunity.<sup><xref ref-type="bibr" rid="bibr7-0003319711416804">7</xref></sup>
</p>
<p>Foot ulcers may be classified in terms of severity, in order to facilitate a logical approach to treatment and aid in the prediction of outcome. The most commonly used classification systems are the Wagner system and the University of Texas (UT) system.<sup><xref ref-type="bibr" rid="bibr1-0003319711416804">1</xref>,<xref ref-type="bibr" rid="bibr5-0003319711416804">5</xref></sup> In the former, grade I ulcers are superficial, involving the full skin thickness but no underlying tissues. Grade II ulcers are deeper, penetrating down to ligaments and muscles, but not involving bone or abscess formation. Grade III ulcers are deep ulcers with cellulitis or abscess formation, often complicated with osteomyelitis. Grade IV ulcers have localized gangrene and grade V ulcers have extensive gangrene involving the entire foot.<sup><xref ref-type="bibr" rid="bibr1-0003319711416804">1</xref></sup> The UT classification system uses 4 grades of ulcer depth (0-3) and 4 stages (A-D), based on ischemia and/or infection, and is predictive of outcome, because wounds of increasing grade and stage are less likely to heal without revascularization or amputation.<sup><xref ref-type="bibr" rid="bibr5-0003319711416804">5</xref></sup> Both the UT and Wagner systems are reliable in predicting the outcome of foot ulcers.<sup><xref ref-type="bibr" rid="bibr8-0003319711416804">8</xref>,<xref ref-type="bibr" rid="bibr9-0003319711416804">9</xref></sup>
</p>
<p>Optimal management of diabetic foot ulcers is best offered by multidisciplinary foot clinics.<sup><xref ref-type="bibr" rid="bibr1-0003319711416804">1</xref><xref ref-type="bibr" rid="bibr2-0003319711416804"/><xref ref-type="bibr" rid="bibr3-0003319711416804"/>–<xref ref-type="bibr" rid="bibr4-0003319711416804">4</xref></sup> Revascularization to restore adequate blood flow as needed, aggressive infection control, and off-loading are the cornerstones of treatment. Off-loading is accomplished by total contact cast or Aircast walker and/or pressure-relief half shoes, in conjunction with debridement of nonviable tissue.<sup><xref ref-type="bibr" rid="bibr1-0003319711416804">1</xref><xref ref-type="bibr" rid="bibr2-0003319711416804"/><xref ref-type="bibr" rid="bibr3-0003319711416804"/>–<xref ref-type="bibr" rid="bibr4-0003319711416804">4</xref>,<xref ref-type="bibr" rid="bibr6-0003319711416804">6</xref></sup> Other emerging therapies are human cultured dermis, human skin equivalent, topical growth factors, wound dressings, and systemic hyperbaric oxygen (HBO).<sup><xref ref-type="bibr" rid="bibr1-0003319711416804">1</xref><xref ref-type="bibr" rid="bibr2-0003319711416804"/><xref ref-type="bibr" rid="bibr3-0003319711416804"/>–<xref ref-type="bibr" rid="bibr4-0003319711416804">4</xref>,<xref ref-type="bibr" rid="bibr10-0003319711416804">10</xref></sup> It must also be stressed that statins are a further valuable treatment, since there is an ever-increasing evidence that they improve pain-free walking distance, reduce morbidity and mortality, and improve ulcer healing in diabetic patients with peripheral arterial disease, mainly owing to their pleiotropic, nonlipid-lowering actions.<sup><xref ref-type="bibr" rid="bibr11-0003319711416804">11</xref><xref ref-type="bibr" rid="bibr12-0003319711416804"/><xref ref-type="bibr" rid="bibr13-0003319711416804"/>–<xref ref-type="bibr" rid="bibr14-0003319711416804">14</xref></sup>
</p>
</sec>
<sec id="section3-0003319711416804">
<title>Hyperbaric Oxygen</title>
<p>Hyperbaric oxygen therapy is defined by the Undersea and Hyperbaric Medical Society as a treatment in which a patient intermittently breathes 100% oxygen, while the treatment chamber is pressurized to a pressure greater than sea level (1 atmosphere absolute [ATA]).<sup><xref ref-type="bibr" rid="bibr15-0003319711416804">15</xref></sup> It was first documented in 1662, when the first hyperbaric chamber was built.<sup><xref ref-type="bibr" rid="bibr16-0003319711416804">16</xref></sup> Nowadays, there are monoplace chambers, accommodating a single patient and pressurized to about 2 to 2.5 ATA with 100% oxygen, and multiplace chambers, accommodating several patients and/or health care personnel and compressed with air up to 2 to 2.5 ATA, while the patient breathes 100% oxygen given via face mask, head tent, or endotracheal tube.<sup><xref ref-type="bibr" rid="bibr17-0003319711416804">17</xref></sup>
</p>
<p>Hyperbaric oxygen is thought to improve tissue hypoxia, enhance perfusion, ameliorate edema, reduce inflammation, and promote fibroblast proliferation, collagen production, and angiogenesis. It may also contribute to the eradication of infections by means of bactericidal activity and improved leukocyte and macrophage function.<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup> In particular, HBO therapy increases both the portion of oxygenated hemoglobin and the portion of oxygen carried in solution, thereby resulting in a multifold increase in tissue oxygen tension and maximizing tissue oxygenation.<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref>,<xref ref-type="bibr" rid="bibr19-0003319711416804">19</xref></sup> This primary effect of HBO generates a favorable gradient for oxygen diffusion from functioning capillaries to ischemic tissue sites. The increment in oxygen supply may be the factor that allows the compromised tissues to survive, and so tissue viability and function are maintained.<sup><xref ref-type="bibr" rid="bibr19-0003319711416804">19</xref></sup> In addition, HBO increases red blood cell flexibility, improving local microcirculation.<sup><xref ref-type="bibr" rid="bibr7-0003319711416804">7</xref></sup> Another beneficial effect of hyperoxygenation in ischemic wounds is the reduction in posttraumatic tissue edema, thanks to vasoconstriction.<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref>,<xref ref-type="bibr" rid="bibr19-0003319711416804">19</xref></sup> Furthermore, HBO enhances replication of fibroblasts, activation of osteoclasts, as well as differentiation and migration of keratinocytes.<sup><xref ref-type="bibr" rid="bibr20-0003319711416804">20</xref></sup> Given that HBO upregulates vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) release,<sup><xref ref-type="bibr" rid="bibr21-0003319711416804">21</xref></sup> a persistent effect following HBO administration appears to be the promotion of collagen matrix formation, epithelialization, angiogenesis,<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup> stimulation of capillary growth, and support of tissue nutrition.<sup><xref ref-type="bibr" rid="bibr6-0003319711416804">6</xref></sup> Moreover, despite some increase in the generation of reactive oxygen species upon its first adminitsration,<sup><xref ref-type="bibr" rid="bibr22-0003319711416804">22</xref></sup> it preserves intracellular ATP<sup><xref ref-type="bibr" rid="bibr4-0003319711416804">4</xref></sup> and decreases lactate accumulation.<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup> Acting on the inflammatory cascade, HBO causes downregulation of inflammatory cytokines, exhibits antibacterial effects, and enhances antibiotic action.<sup><xref ref-type="bibr" rid="bibr23-0003319711416804">23</xref>,<xref ref-type="bibr" rid="bibr24-0003319711416804">24</xref></sup> Oxygen free radicals damage bacterial DNA and inhibit their metabolic actions.<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup> In addition, HBO is particularly effective against anaerobes<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup> and facilitates the killing activity of polymorphonuclear leukocytes<sup><xref ref-type="bibr" rid="bibr19-0003319711416804">19</xref></sup> and phagocytes.<sup><xref ref-type="bibr" rid="bibr6-0003319711416804">6</xref></sup> It also improves tissue concentration of antibiotics at the site of lower extremity ulcers,<sup><xref ref-type="bibr" rid="bibr25-0003319711416804">25</xref></sup> as well as their transport across bacterial cell walls.<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup> Furthermore, HBO seems to be beneficial in osteomyelitis and soft tissue infections.<sup><xref ref-type="bibr" rid="bibr7-0003319711416804">7</xref>,<xref ref-type="bibr" rid="bibr24-0003319711416804">24</xref></sup> These advantageous effects of HBO are attributable to the intracellular generation of reactive oxygen species and nitric oxide, both playing a central role in cell signal transduction cascades.<sup><xref ref-type="bibr" rid="bibr26-0003319711416804">26</xref><xref ref-type="bibr" rid="bibr27-0003319711416804"/><xref ref-type="bibr" rid="bibr28-0003319711416804"/>–<xref ref-type="bibr" rid="bibr29-0003319711416804">29</xref></sup>
</p>
<p>Based on these beneficial effects, HBO therapy has been used for the treatment of various conditions.<sup><xref ref-type="bibr" rid="bibr30-0003319711416804">30</xref></sup> In general, HBO should be considered whenever gas bubbles are present in tissue or blood circulation (decompression sickness, gas embolism) or when a high oxygen delivery is of crucial importance (CO-intoxication, selected anaerobic soft tissue infections, anemia, wound treatment, radiation injury, reperfusion injury, and neurologic conditions; <xref ref-type="table" rid="table1-0003319711416804">Table 1</xref>
).<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref>,<xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref><xref ref-type="bibr" rid="bibr32-0003319711416804"/><xref ref-type="bibr" rid="bibr33-0003319711416804"/><xref ref-type="bibr" rid="bibr34-0003319711416804"/><xref ref-type="bibr" rid="bibr35-0003319711416804"/><xref ref-type="bibr" rid="bibr36-0003319711416804"/><xref ref-type="bibr" rid="bibr37-0003319711416804"/><xref ref-type="bibr" rid="bibr38-0003319711416804"/><xref ref-type="bibr" rid="bibr39-0003319711416804"/><xref ref-type="bibr" rid="bibr40-0003319711416804"/><xref ref-type="bibr" rid="bibr41-0003319711416804"/><xref ref-type="bibr" rid="bibr42-0003319711416804"/><xref ref-type="bibr" rid="bibr43-0003319711416804"/><xref ref-type="bibr" rid="bibr44-0003319711416804"/><xref ref-type="bibr" rid="bibr45-0003319711416804"/><xref ref-type="bibr" rid="bibr46-0003319711416804"/><xref ref-type="bibr" rid="bibr47-0003319711416804"/><xref ref-type="bibr" rid="bibr48-0003319711416804"/><xref ref-type="bibr" rid="bibr49-0003319711416804"/>–<xref ref-type="bibr" rid="bibr50-0003319711416804">50</xref></sup> Precaution should be taken to avoid adverse effects. The most common of these include ophthalmopathies (such as progressive, reversible myopia, and cataract formation), central nervous system toxicity and seizures, ear traumas (such as middle and inner ear barotraumas, otitis media, and tympanic rapture), dental barotraumas, pulmonary barotraumas and pneumothorax, fetal complications during pregnancy (such as spina bifida), as well as claustrophobia and fire accident.<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref>,<xref ref-type="bibr" rid="bibr26-0003319711416804">26</xref></sup> Theoretically, stimulation of angiogenesis by HBO might enhance vascular growth within malignancies, although current evidence does not support this concern.<sup><xref ref-type="bibr" rid="bibr6-0003319711416804">6</xref></sup> Importantly, patients with history of recent ear or sinus surgery, seizure disorders, febrile disorders, certain chemotherapies (due to increased pulmonary toxicity), upper respiratory infections, emphysema, thoracic surgery or pneumothorax, pacemakers, optic neuritis or otosclerosis, viral infections, congenital spherocytosis, hyperthermia, claustrophobia, and pregnancy should be excluded from HBO therapy.<sup><xref ref-type="bibr" rid="bibr20-0003319711416804">20</xref></sup>
</p>
<table-wrap id="table1-0003319711416804" position="float">
<label>Table 1.</label>
<caption>
<p>Indications for Hyperbaric Oxygen Treatment</p>
</caption>
<graphic alternate-form-of="table1-0003319711416804" xlink:href="10.1177_0003319711416804-table1.tif"/>
<table>
<tbody>
<tr>
<td>Anemia<break/> Exceptional blood loss anemia<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup>
<break/> Sickle cell crisis<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref></sup>
<break/>Decompression sickness<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref>,<xref ref-type="bibr" rid="bibr32-0003319711416804">32</xref></sup>
<break/>Delayed radiation injury<break/> Head and neck<break/>  Laryngeal radionecrosis<sup><xref ref-type="bibr" rid="bibr33-0003319711416804">33</xref></sup>
<break/> Necrosis of the brain<sup><xref ref-type="bibr" rid="bibr33-0003319711416804">33</xref></sup>
<break/>  Optic neuropathy<sup><xref ref-type="bibr" rid="bibr33-0003319711416804">33</xref></sup>
<break/>  Salivary gland damage<sup><xref ref-type="bibr" rid="bibr34-0003319711416804">34</xref></sup>
<break/> Abdomen<sup><xref ref-type="bibr" rid="bibr35-0003319711416804">35</xref></sup>
<break/>  Gastrointestinal radiation injury<sup><xref ref-type="bibr" rid="bibr36-0003319711416804">36</xref></sup>
<break/> Pelvis<sup><xref ref-type="bibr" rid="bibr35-0003319711416804">35</xref></sup>
<break/>  Proctitis<sup><xref ref-type="bibr" rid="bibr33-0003319711416804">33</xref></sup>
<break/>Symptomatic radiation reactions of the urinary bladder<sup><xref ref-type="bibr" rid="bibr33-0003319711416804">33</xref>,<xref ref-type="bibr" rid="bibr37-0003319711416804">37</xref></sup>
<break/> Soft tissue and bony necrosis<sup><xref ref-type="bibr" rid="bibr33-0003319711416804">33</xref></sup>
<break/>Enhancement of healing in selected problem wounds<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref>,<xref ref-type="bibr" rid="bibr38-0003319711416804">38</xref></sup>
<break/>Infections<break/> Bones<break/>  Refractory osteomyelitis<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup>
<break/> Gastrointestinal system<break/>  Intra-abdominal abscess<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref></sup>
<break/>  Pseudomonas colitis<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref></sup>
<break/> Soft tissues<break/>  Actinomycosis<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup>
<break/>  Clostridial myositis and myonecrosis (gas gangrene)<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup>
<break/>  Cutaneous/soft-tissue zygomycosis complicating diabetes mellitus<sup><xref ref-type="bibr" rid="bibr39-0003319711416804">39</xref></sup>
<break/>  Fournier gangrene<sup><xref ref-type="bibr" rid="bibr40-0003319711416804">40</xref></sup>
<break/>  Lepromatous leprosy<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref></sup>
<break/>  Necrotizing soft tissue infections<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup>
<break/> Urinary system<break/>  Chronic pelvic pain<sup><xref ref-type="bibr" rid="bibr41-0003319711416804">41</xref></sup>
<break/>  Interstitial cystitis<sup><xref ref-type="bibr" rid="bibr41-0003319711416804">41</xref></sup>
<break/>  Radiation-induced cystitis<sup><xref ref-type="bibr" rid="bibr41-0003319711416804">41</xref></sup>
<break/>  Scrotoperineal fasciitis<sup><xref ref-type="bibr" rid="bibr41-0003319711416804">41</xref></sup>
<break/>Injuries<break/> Acute traumatic peripheral ischemia<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup>
<break/> Compartment syndromes<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup>
<break/> Crush injury<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref>,<xref ref-type="bibr" rid="bibr42-0003319711416804">42</xref></sup>
<break/> Fracture healing and bone grafting<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref></sup>
<break/> Head injuries<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref>,<xref ref-type="bibr" rid="bibr43-0003319711416804">43</xref></sup>
<break/> Skin flaps and grafts (compromised)<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup>
<break/> Spinal cord injury<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref></sup>
<break/> Thermal burns<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup>
<break/> Treatment of open fractures<sup><xref ref-type="bibr" rid="bibr42-0003319711416804">42</xref></sup>
<break/>Nervous system<break/> Acute cerebrovascular incidents<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref></sup>
<break/> Acute focal cerebral ischemia<sup><xref ref-type="bibr" rid="bibr45-0003319711416804">45</xref></sup>
<break/> Autism<sup><xref ref-type="bibr" rid="bibr46-0003319711416804">46</xref></sup>
<break/> Cerebral edema<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref></sup>
<break/> Intracranial abscess<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup>
<break/> Spinal cord injury<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref></sup>
<break/> Treatment of hypertensive intracerebral hemorrhage<sup><xref ref-type="bibr" rid="bibr47-0003319711416804">47</xref></sup>
<break/>Obstruction<break/> Acute central retinal artery insufficiency<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref></sup>
<break/> Embolism (air or gas)<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup>
<break/> Ischemia–reperfusion injury<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref></sup>
<break/>Poisoning<break/> Brown recluse spider bite<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref></sup>
<break/> Carbon monoxide<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref>,<xref ref-type="bibr" rid="bibr48-0003319711416804">48</xref>,<xref ref-type="bibr" rid="bibr49-0003319711416804">49</xref></sup>
<break/> Carbon tetrachloride<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref></sup>
<break/> Cyanide<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref></sup>
<break/> Hydrogen sulfate<sup><xref ref-type="bibr" rid="bibr31-0003319711416804">31</xref></sup>
<break/>Smoke inhalation<sup><xref ref-type="bibr" rid="bibr18-0003319711416804">18</xref>,<xref ref-type="bibr" rid="bibr50-0003319711416804">50</xref></sup>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
</sec>
<sec id="section4-0003319711416804">
<title>Hyperbaric Oxygen in Diabetic Foot Ulcers</title>
<sec id="section5-0003319711416804">
<title>Beneficial Effects</title>
<p>Hyperbaric oxygen may help in complete or partial wound healing, as well as reduction in amputation rates.</p>
<sec id="section6-0003319711416804">
<title>Impact on ulcer healing</title>
<p>The vast majority of participants in available studies have chronic, nonhealing ulcers. Taken together, studies provide evidence on the contribution of HBO to ulcer healing (<xref ref-type="table" rid="table2-0003319711416804">Table 2</xref>
).<sup><xref ref-type="bibr" rid="bibr51-0003319711416804">51</xref><xref ref-type="bibr" rid="bibr52-0003319711416804"/><xref ref-type="bibr" rid="bibr53-0003319711416804"/><xref ref-type="bibr" rid="bibr54-0003319711416804"/><xref ref-type="bibr" rid="bibr55-0003319711416804"/><xref ref-type="bibr" rid="bibr56-0003319711416804"/><xref ref-type="bibr" rid="bibr57-0003319711416804"/><xref ref-type="bibr" rid="bibr58-0003319711416804"/><xref ref-type="bibr" rid="bibr59-0003319711416804"/><xref ref-type="bibr" rid="bibr60-0003319711416804"/><xref ref-type="bibr" rid="bibr61-0003319711416804"/>–<xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref></sup> Data derived from small prospective nonrandomized controlled<sup><xref ref-type="bibr" rid="bibr51-0003319711416804">51</xref>,<xref ref-type="bibr" rid="bibr52-0003319711416804">52</xref>,<xref ref-type="bibr" rid="bibr54-0003319711416804">54</xref></sup> and retrospective trials<sup><xref ref-type="bibr" rid="bibr59-0003319711416804">59</xref><xref ref-type="bibr" rid="bibr60-0003319711416804"/>–<xref ref-type="bibr" rid="bibr61-0003319711416804">61</xref></sup> have shown higher wound reduction and healing rates in HBO-treated patients than those receiving standard treatment alone. This beneficial effect is supported by more robust evidence from recently published randomized studies.<sup><xref ref-type="bibr" rid="bibr53-0003319711416804">53</xref>,<xref ref-type="bibr" rid="bibr55-0003319711416804">55</xref><xref ref-type="bibr" rid="bibr56-0003319711416804"/><xref ref-type="bibr" rid="bibr57-0003319711416804"/>–<xref ref-type="bibr" rid="bibr58-0003319711416804">58</xref>,<xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref></sup> Duration of the beneficial effect of HBO is evidenced by follow-up up to 3 years.<sup><xref ref-type="bibr" rid="bibr53-0003319711416804">53</xref><xref ref-type="bibr" rid="bibr54-0003319711416804"/><xref ref-type="bibr" rid="bibr55-0003319711416804"/><xref ref-type="bibr" rid="bibr56-0003319711416804"/><xref ref-type="bibr" rid="bibr57-0003319711416804"/><xref ref-type="bibr" rid="bibr58-0003319711416804"/><xref ref-type="bibr" rid="bibr59-0003319711416804"/>–<xref ref-type="bibr" rid="bibr60-0003319711416804">60</xref>,<xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref></sup> The first randomized, double-blind, controlled clinical trial supporting the use of HBO as a therapeutic adjunct in the healing of chronic diabetic foot ulcers was performed by Abidia et al<sup><xref ref-type="bibr" rid="bibr57-0003319711416804">57</xref></sup> in 2003. In the HBO group, healing was achieved in 63% of patients at 6 months compared to 28% in the control group.<sup><xref ref-type="bibr" rid="bibr57-0003319711416804">57</xref></sup> Currently, the efficacy of HBO treatment is supported by a Cochrane meta-analysis<sup><xref ref-type="bibr" rid="bibr63-0003319711416804">63</xref></sup> as well as plenty of systematic reviews.<sup><xref ref-type="bibr" rid="bibr6-0003319711416804">6</xref>,<xref ref-type="bibr" rid="bibr17-0003319711416804">17</xref>,<xref ref-type="bibr" rid="bibr23-0003319711416804">23</xref></sup> A significant improvement in the chance of healing at 1 year after therapy has now been documented (odds ratio of healing with HBO compared with sham treatment 2.3, 95% confidence interval [CI]: 1.1-4.7, <italic>P</italic> = .03). A more recent double-blind clinical trial<sup><xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref></sup> has strengthened the evidence in favor of HBO.<sup><xref ref-type="bibr" rid="bibr64-0003319711416804">64</xref>,<xref ref-type="bibr" rid="bibr65-0003319711416804">65</xref></sup> All patients in this study had chronic, neuropathic, or neuroischemic wounds and vascular assessment had indicated that they were poor candidates for revascularization. An intention-to-treat analysis showed an improvement in ulcer healing (HBO group 52% vs control group 29%, <italic>P</italic> = .03). The additional benefit conferred by HBO was revealed in the per-protocol analysis (HBO group 61% vs control group 27%, <italic>P</italic> = .009) among participants completing more than 35 sessions of HBO.<sup><xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref></sup> As already pointed out, only 56% of eligible patients were enrolled, and only 57% of these completed the 40 scheduled treatments (although 80% at least 35).<sup><xref ref-type="bibr" rid="bibr66-0003319711416804">66</xref></sup> This may be seen as a limitation of the study, but it may also be taken to denote that results would have been better, had more patients complete scheduled treatment. Overall, the long-term ulcer healing rates of nonrandomized studies (77% with HBO vs 25% with standard treatment) are similar to 1-year follow-up data from the 2 double-blinded randomized control trials (54% vs 24%, respectively).<sup><xref ref-type="bibr" rid="bibr67-0003319711416804">67</xref></sup>
</p>
<table-wrap id="table2-0003319711416804" position="float">
<label>Table 2.</label>
<caption>
<p>Studies That Present Healing Rates of Diabetic Ulcers After HBO Treatment</p>
</caption>
<graphic alternate-form-of="table2-0003319711416804" xlink:href="10.1177_0003319711416804-table2.tif"/>
<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Participants</th>
<th>HBO</th>
<th>Healing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baroni et al<sup><xref ref-type="bibr" rid="bibr51-0003319711416804">51</xref></sup>
</td>
<td>PS NR C Surgeon-blinded FU by Faglia, Oriani</td>
<td>28 DM Wagner 3-4 I: 18 (SC + HBO) C: 10 (SC)</td>
<td>2,5-2,8ATA× 90 min mn 34 tr</td>
<td>I: 16/18 (89%) C: 1/10 (10%)</td>
</tr>
<tr>
<td>Oriani et al<sup><xref ref-type="bibr" rid="bibr52-0003319711416804">52</xref></sup>
</td>
<td>PS NR C FU-</td>
<td>80 DM Wagner 4-5 I: 62 (SC + HBO) C: 18 (SC)</td>
<td>2,5-2,8ATA mn 72 tr</td>
<td>I: 41/62 (66%) C: 6/18 (33%)</td>
</tr>
<tr>
<td>Faglia et al<sup><xref ref-type="bibr" rid="bibr53-0003319711416804">53</xref></sup>
</td>
<td>PS R C FU 7 w</td>
<td>68 DM Wagner 2-4 I: 26 (SC + HBO) C: 20 (SC)</td>
<td>2,5ATA × 90 min mn 38 tr</td>
<td>I: 24/26 (92.3%) C: 2/20 (10%)</td>
</tr>
<tr>
<td>Zamboni et al<sup><xref ref-type="bibr" rid="bibr54-0003319711416804">54</xref></sup>
</td>
<td>PS NR C FU 4-6 m</td>
<td>15 DM + chronic foot ulcers I: 5 (SC + HBO) C: 5 (SC)</td>
<td>2,0ATA × 120 m mn 30 tr</td>
<td>Reduction I: 4/5 (80%) C: 1/5 (20%)</td>
</tr>
<tr>
<td>Kalani et al<sup><xref ref-type="bibr" rid="bibr55-0003319711416804">55</xref></sup>
</td>
<td>PS R C FU 3 y</td>
<td>38 DM aTcPO<sub>2</sub> &lt;40 mm Hg oTcPO<sub>2</sub> &gt;10 mm Hg ↑ I: 17 (SC + HBO) C: 21 (SC)</td>
<td>2,5ATA× 90 min mn 40-60 tr</td>
<td>I: 13/17 (76%) C: 10/21 (48%)</td>
</tr>
<tr>
<td>Kessler et al<sup><xref ref-type="bibr" rid="bibr56-0003319711416804">56</xref></sup>
</td>
<td>PS R C FU 4 w (lost I: 1)</td>
<td>28 DM+neuropathy Wagner 1-3 d &gt;3m I: 14 (SC + HBO) C: 13 (SC)</td>
<td>2,5 ATA × 90 min mn 20 tr</td>
<td>Reduction I: 6/14 (42%) C: 3/13 (22%) FU 2 w Reduction I: 7/14 (48%) 0C: 5/13 (42%) FU 4 w Reduction I: 9/14 (62%) C: 7/13 (55%) FU Healing 4w I: 2/14 (14%) C:0/13 (0%)</td>
</tr>
<tr>
<td>Abidia et al<sup><xref ref-type="bibr" rid="bibr57-0003319711416804">57</xref></sup>
</td>
<td>PS R C T double-blinded FU 1 y (lost 2, I 1, C 1)</td>
<td>18 DM Wagner 1-2 d &gt; 6w ABI &lt;0.8 TBP &lt;0.7 I: 9 (SC+HBO) C: 9 (SC+AIR)</td>
<td>2.4 ATA× 90 min mn 30 tr</td>
<td>6 w I: 5/8 (63%) C: 1/8 (13%) 6m I: 5/8 (63%) C: 2/8 (28%) 1y I: 5/8 (63%) C: 0/8 (0%)</td>
</tr>
<tr>
<td>Duzgun et al<sup><xref ref-type="bibr" rid="bibr58-0003319711416804">58</xref></sup>
</td>
<td>PS R C FU 92 w</td>
<td>100 DM Wagner 2-4 ≥4 w I: 50 (SC + HBO) C: 50 (SC)</td>
<td>2,5ATA × 90 min mn 30-45 tr</td>
<td>No debridement I: 33/50 (66%) C: 0/50 (0%) After graft I: 4/50 (8%) C: 0 (0%)</td>
</tr>
<tr>
<td>Lyon<sup><xref ref-type="bibr" rid="bibr59-0003319711416804">59</xref></sup>
</td>
<td>RS NR C FU 8 w</td>
<td>89 DM Ulcer &gt;30 d A: 25 SC B: 26 PDGF C: 13 SC + HBO D: 25 HBO + PDGF</td>
<td>NR aTcPO2 &gt; 30 mm Hg cTcPO2 &gt; 500 mm Hg</td>
<td>Reduction A: 15% B: 82% C: 30% D: 72%</td>
</tr>
<tr>
<td>Kaya et al<sup><xref ref-type="bibr" rid="bibr60-0003319711416804">60</xref></sup>
</td>
<td>PS NR UC FU 1 y</td>
<td>184 DM Wagner 2-5 SC + HBO</td>
<td>2.4 ATA × 120min mn 39 tr</td>
<td>115/184 (62,5%)</td>
</tr>
<tr>
<td>Chen et al<sup><xref ref-type="bibr" rid="bibr61-0003319711416804">61</xref></sup>
</td>
<td>PS NR C FU-</td>
<td>42 DM 44 infected feet I: 21 (&gt;10 HBO) C: 21 (&lt;10 HBO)</td>
<td>NR</td>
<td>I: 16/21 (76,2%) C: 7/21 (33,3%)</td>
</tr>
<tr>
<td>Löndahl et al<sup><xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref></sup>
</td>
<td>PS R C T double-blinded FU 1 y</td>
<td>94 DM Wagner 2-4 &gt;3m I: 49 (SC + HBO) C: 45 (SC + AIR)</td>
<td>2.5 ATA × 90 min mn 40 tr</td>
<td>ITTA I: 25/48 (52%) C: 12/42 (29%) PPA I: 23/38 (61%) C: 10/37 (27%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319711416804">
<p>Abbreviations: HBO, hyperbaric oxygen; PS, prospective; NR, non-randomized; C, controlled; FU, follow-up; DM, diabetes mellitus; I, intervention group; C, control group; SC, standard care treatment; ATA, atmosphere absolute; min, minutes; mn, mean; tr, treatments; UC, uncontrolled; R, randomized; w, weeks; m, months; y, years; aTcPO2, transcutaneous oxymetry in air; oTcPO<sub>2</sub>, transcutaneous oxymetry in 100% O<sub>2</sub>; ↑, increase; T, trial; d, duration; ABI, ankle–brachial index; TBP, arterial toe blood pressure; NR, not recorded; cTcPO<sub>2</sub>, transcutaneous oxymetry in chamber; ITTA, intention-to-treat analysis; PPA, per protocol analysis</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-0003319711416804">
<title>Impact on amputation</title>
<p>The outcome of unsuccessful treatment of diabetic foot ulcers is usually amputation, especially in cases of inadequate peripheral circulation. Additional therapies, like HBO, have tried to reduce amputation rates. Pooled analysis of data revealed that patients managed by HBO therapy had a significantly reduced risk of major, but not minor amputations, compared with controls (<xref ref-type="table" rid="table3-0003319711416804">Table 3</xref>
),<sup><xref ref-type="bibr" rid="bibr51-0003319711416804">51</xref><xref ref-type="bibr" rid="bibr52-0003319711416804"/>–<xref ref-type="bibr" rid="bibr53-0003319711416804">53</xref>,<xref ref-type="bibr" rid="bibr55-0003319711416804">55</xref>,<xref ref-type="bibr" rid="bibr57-0003319711416804">57</xref>,<xref ref-type="bibr" rid="bibr58-0003319711416804">58</xref>,<xref ref-type="bibr" rid="bibr60-0003319711416804">60</xref><xref ref-type="bibr" rid="bibr61-0003319711416804"/>–<xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref>,<xref ref-type="bibr" rid="bibr68-0003319711416804">68</xref><xref ref-type="bibr" rid="bibr69-0003319711416804"/><xref ref-type="bibr" rid="bibr70-0003319711416804"/><xref ref-type="bibr" rid="bibr71-0003319711416804"/><xref ref-type="bibr" rid="bibr72-0003319711416804"/>–<xref ref-type="bibr" rid="bibr73-0003319711416804">73</xref></sup> as mentioned in the systematic reviews by Wang et al,<sup><xref ref-type="bibr" rid="bibr17-0003319711416804">17</xref></sup> Roeckl-Wiedmann et al,<sup><xref ref-type="bibr" rid="bibr23-0003319711416804">23</xref></sup> and Gray et al.<sup><xref ref-type="bibr" rid="bibr74-0003319711416804">74</xref></sup> This concurs with the meta-analysis by Kranke et al,<sup><xref ref-type="bibr" rid="bibr63-0003319711416804">63</xref></sup> which demonstrated a reduction in the risk of major amputation with add-on HBO therapy (relative risk 0.31, 95% CI: 0.13-0.71), compared with standard treatment. This meta-analysis predicted that 4 participants would need to be treated with HBO therapy in order to prevent 1 amputation in the short term (95%CI: 3-11). Although the risk reduction for major amputations in patients with severely infected diabetic foot ulcers is promising, the quality of evidence and consistency of results are still low.<sup><xref ref-type="bibr" rid="bibr75-0003319711416804">75</xref></sup> In an effort to clarify the situation, further studies have been performed. In a randomized trial, Duzgun et al<sup><xref ref-type="bibr" rid="bibr58-0003319711416804">58</xref></sup> found that HBO therapy was associated with fewer lower extremity amputations, while Löndahl et al<sup><xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref></sup> have recently performed a double-blinded trial, in which the rates of major amputation were similar for the 2 groups and relatively low, rendering the judgment on the efficacy of HBO very difficult.<sup><xref ref-type="bibr" rid="bibr66-0003319711416804">66</xref></sup> The higher incidence of amputation rates observed in control groups in the earlier nonblinded randomized control trials, compared with more recent double-blinded ones by Abidia et al<sup><xref ref-type="bibr" rid="bibr57-0003319711416804">57</xref></sup> and Löndahl et al<sup><xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref></sup> could reflect a change in indications for major amputation, as discussed by Löndahl et al.<sup><xref ref-type="bibr" rid="bibr67-0003319711416804">67</xref></sup>
</p>
<table-wrap id="table3-0003319711416804" position="float">
<label>Table 3.</label>
<caption>
<p>Studies That Present Amputation Rates of Diabetic Ulcers After HBO Treatment</p>
</caption>
<graphic alternate-form-of="table3-0003319711416804" xlink:href="10.1177_0003319711416804-table3.tif"/>
<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Participants</th>
<th>HBO</th>
<th>Amputation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baroni et al<sup><xref ref-type="bibr" rid="bibr51-0003319711416804">51</xref></sup>
</td>
<td>PS NR C Surgeon-blinded FU by Faglia, Oriani</td>
<td>28 DM Wagner 3-4 I: 18 (SC + HBO) C: 10 (SC)</td>
<td>2.5-2.8 ATA × 90 min mn 34 tr</td>
<td>I: 2/18 (11.1%) C: 4/10 (40%)</td>
</tr>
<tr>
<td>Oriani et al<sup><xref ref-type="bibr" rid="bibr52-0003319711416804">52</xref></sup>
</td>
<td>PS NR C FU-</td>
<td>80 DM Wagner 4-5 I: 62 (SC + HBO) C: 18 (SC)</td>
<td>2.5-2.8 ATA mn 72 tr</td>
<td>I: 3/62 (5%) C: 6/18 (33%)</td>
</tr>
<tr>
<td>Cianci et al<sup><xref ref-type="bibr" rid="bibr68-0003319711416804">68</xref></sup>
</td>
<td>PS NR UC FU-</td>
<td>41 DM Wagner 4</td>
<td>2.0 ATA × 90-120 min mn 37 tr</td>
<td>10/41 (24%)</td>
</tr>
<tr>
<td>Wattel et al<sup><xref ref-type="bibr" rid="bibr69-0003319711416804">69</xref></sup>
</td>
<td>RS NR UC FU-</td>
<td>59 DM with foot ulcers</td>
<td>2.5 ATA × 90 min mn 29 tr</td>
<td>7/59 (12%)</td>
</tr>
<tr>
<td>Doctor et al<sup><xref ref-type="bibr" rid="bibr70-0003319711416804">70</xref></sup>
</td>
<td>RS R C T At discharge FU-</td>
<td>30 DM 23 gangrene 5 neuropathic ulcers I: 15 (SC + HBO) C: 15 (SC)</td>
<td>3 ATA × 45 min mn 4tr</td>
<td>Major I: 2/15 (13%) C: 7/15 (47%) Minor I: 4/15 (27%) C: 2/15 (13%)</td>
</tr>
<tr>
<td>Faglia et al<sup><xref ref-type="bibr" rid="bibr53-0003319711416804">53</xref></sup>
</td>
<td>PS R C T FU 7w</td>
<td>68 DM Wagner 2-4 I: 35 (SC + HBO) C: 33 (SC)</td>
<td>2.5 ATA × 90 min mn 38 tr</td>
<td>I: 33/35 (8.6%) C: 11/33 (33.3%)</td>
</tr>
<tr>
<td>Stone et al<sup><xref ref-type="bibr" rid="bibr71-0003319711416804">71</xref></sup>
</td>
<td>RS R C Review</td>
<td>501 DM Ischemic ulcers I: 119 (SC + HBO) C: 382 (SC)</td>
<td>NR</td>
<td>I: 31/119 (26%) C: 19/382 (5%)</td>
</tr>
<tr>
<td>Faglia et al<sup><xref ref-type="bibr" rid="bibr72-0003319711416804">72</xref></sup>
</td>
<td>PS R C T</td>
<td>115 DM Wagner 2-4 I: 51 (SC+HBO) C: 64 (SC)</td>
<td>2.5 ATA × 90 min mn 32tr</td>
<td>Major I: 7/51 (12.9%) C: 20/64 (32.7%)</td>
</tr>
<tr>
<td>Kalani et al<sup><xref ref-type="bibr" rid="bibr55-0003319711416804">55</xref></sup>
</td>
<td>PS R C T FU 3y</td>
<td>38 DM aTcPO<sub>2</sub> &lt;40mm Hg oTcPO<sub>2</sub> &gt;10 mm Hg ↑ I: 17 (SC + HBO) C: 21 (SC)</td>
<td>2.5 ATA × 90 min mn 40-60 tr</td>
<td>I: 2/17 (12%) C: 7/21 (33%)</td>
</tr>
<tr>
<td>Abidia et al<sup><xref ref-type="bibr" rid="bibr57-0003319711416804">57</xref></sup>
</td>
<td>PS R C T double-blinded FU 1 y (lost 2, I 1, C 1)</td>
<td>18 DM Wagner 1-2 d &gt; 6w ABI&lt;0.8 TBI&lt;0.7 I: 9 (SC + HBO) C: 9 (SC + AIR)</td>
<td>2.4 ATA × 90 min mn 30 tr</td>
<td>Major I: 1/9 (13%) C: 0/9 (0%) Minor I:1/9 (13%) C: 1/9 (13%)</td>
</tr>
<tr>
<td>Ong<sup><xref ref-type="bibr" rid="bibr73-0003319711416804">73</xref></sup>
</td>
<td>RS NR UC FU-</td>
<td>45 DM Diabetic ulcers</td>
<td>2.5 ATA × 90 min × 5/7</td>
<td>34/45 (77%) risk for amputation</td>
</tr>
<tr>
<td>Duzgun et al<sup><xref ref-type="bibr" rid="bibr58-0003319711416804">58</xref></sup>
</td>
<td>PS R C T FU 92 w</td>
<td>100 DM Wagner 2-4 d ≥ 4w I: 50 (SC + HBO) C: 50 (SC)</td>
<td>2.5 ATA × 90 min mn 30-45 tr</td>
<td>Major I: 4/50 (8%) C: 24/50 (48%)</td>
</tr>
<tr>
<td>Kaya et al<sup><xref ref-type="bibr" rid="bibr60-0003319711416804">60</xref></sup>
</td>
<td>PS NR UC FU 1 y</td>
<td>184 DM Wagner 2-5 SC + HBO</td>
<td>2.4 ATA × 120 min mn 39 tr</td>
<td>Major 9/184 (4,9%) Minor 29/184 (15,8%)</td>
</tr>
<tr>
<td>Chen et al<sup><xref ref-type="bibr" rid="bibr61-0003319711416804">61</xref></sup>
</td>
<td>PS NR C FU-</td>
<td>42 DM 44 infected feet I: 21 (&gt;10 HBO) C: 21 (&lt;10 HB0)</td>
<td>NR</td>
<td>I: 5/21 (21,7%) C: 14/21 (66,7%)</td>
</tr>
<tr>
<td>Löndahl et al<sup><xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref></sup>
</td>
<td>PS R C T double-blinded FU 1 y</td>
<td>94 DM Wagner 2-4 &gt;3m I: 49 (SC + HBO) C: 45 (SC + AIR)</td>
<td>2.5 ATA × 90 min mn 40 tr</td>
<td>ITTA Major I: 3/49 (7%) C: 1/45 (3%) ITTA Minor I: 4/49 (8%) C: 4/45 (9%) PPA Major I: 1/49 (3%) C: 1/45 (3%) PPA Minor I: 4/49 (11%) C: 4/45 (8%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0003319711416804">
<p>Abbreviations: HBO, hyperbaric oxygen; PS, prospective; NR, non-randomized; C, controlled; FU, follow-up; DM, diabetes mellitus; I, intervention group; C, control group; SC, standard care treatment; ATA, atmosphere absolute; min, minutes; mn, mean; tr, treatments; RS, retrospective; UC, uncontrolled; R, randomized; w, weeks; m, months; y, years; aTcPO<sub>2</sub>, transcutaneous oxymetry in air; oTcPO<sub>2</sub>, transcutaneous oxymetry in 100% O2; ↑, increase; T, trial; d, duration; ABI, ankle–brachial index; TBP, arterial toe blood pressure; NR, not recorded; ITTA, intention-to-treat analysis; PPA, per protocol analysis.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section9-0003319711416804">
<title>Impact on quality of life</title>
<p>In addition to wound healing, HBO may have a substantial psychological impact.<sup><xref ref-type="bibr" rid="bibr67-0003319711416804">67</xref></sup> Short-term results from the Hyperbaric Oxygen Therapy in Diabetics with Chronic Foot Ulcers (HODFU) study have shown that patients receiving HBO were satisfied with their treatment and communicated well with other participants.<sup><xref ref-type="bibr" rid="bibr76-0003319711416804">76</xref></sup> This was achieved despite patients' fears of future health and the risk of amputation, as well as the limitations imposed by time-consuming HBO treatment on everyday activities and social life.<sup><xref ref-type="bibr" rid="bibr76-0003319711416804">76</xref></sup> In the long term, HBO therapy has been associated with improved quality of life. In particular, Lin et al<sup><xref ref-type="bibr" rid="bibr77-0003319711416804">77</xref></sup> in a small study (11 patients) found an improvement in the overall quality of life score, which correlated positively with the Strauss wound classification system and negatively with self-perceived wound severity. In 18 patients, Abidia et al<sup><xref ref-type="bibr" rid="bibr57-0003319711416804">57</xref></sup> also found an improvement in the well-being, as evaluated by the domains of general health and vitality in the SF-36 questionnaire. Similarly, Löndahl et al<sup><xref ref-type="bibr" rid="bibr78-0003319711416804">78</xref></sup> in a larger sample (n = 75) observed a reduction in limitations due to physical and emotional health and a progress in mental health summary score. These effects were sustainable even 1 year after HBO therapy.<sup><xref ref-type="bibr" rid="bibr78-0003319711416804">78</xref></sup>
</p>
</sec>
<sec id="section10-0003319711416804">
<title>Impact on comorbidities</title>
<p>Diabetic patients with lower extremity wounds usually have substantial comorbidities. In the foot itself, a major complication of ulceration is development of osteomyelitis. Despite some indication of a positive effect, there is no firm evidence on the effect of HBO on osteomyelitis.<sup><xref ref-type="bibr" rid="bibr79-0003319711416804">79</xref>,<xref ref-type="bibr" rid="bibr80-0003319711416804">80</xref></sup> In terms of general health, diabetic foot patients may have significant cardiovascular morbidity. Small, nonrandomized studies testify to some beneficial actions of HBO on myocardial diastolic function, blood pressure, and heart rate.<sup><xref ref-type="bibr" rid="bibr81-0003319711416804">81</xref>,<xref ref-type="bibr" rid="bibr82-0003319711416804">82</xref></sup> Hyperbaric oxygen may also reduce the risk of malignant ventricular arrhythmia and sudden cardiac death.<sup><xref ref-type="bibr" rid="bibr81-0003319711416804">81</xref></sup> In addition, HBO therapy may have beneficial effects on atherosclerosis and glycemic control,<sup><xref ref-type="bibr" rid="bibr82-0003319711416804">82</xref>,<xref ref-type="bibr" rid="bibr83-0003319711416804">83</xref></sup> even though the evidence from animal studies is rather contradictory.<sup><xref ref-type="bibr" rid="bibr84-0003319711416804">84</xref>,<xref ref-type="bibr" rid="bibr85-0003319711416804">85</xref></sup>
</p>
</sec>
</sec>
<sec id="section11-0003319711416804">
<title>Contraindications and Concerns</title>
<p>While the benefits of HBO therapy are increasingly appreciated, it is important to be aware of its adverse effects and take into consideration the cost imposed on the health care system by its widespread HBO application. The decision to include HBO in the clinical armamentarium must be a balance between effectiveness, cost, and safety.</p>
<sec id="section12-0003319711416804">
<title>Side effects</title>
<p>As mentioned above, HBO may be accompanied by untoward effects. Regrettably, some studies provided no information on adverse effects.<sup><xref ref-type="bibr" rid="bibr70-0003319711416804">70</xref>,<xref ref-type="bibr" rid="bibr72-0003319711416804">72</xref>,<xref ref-type="bibr" rid="bibr76-0003319711416804">76</xref></sup> Abidia et al<sup><xref ref-type="bibr" rid="bibr57-0003319711416804">57</xref></sup> found no adverse events related to HBO during the study period. In most of the studies, mild side effects were reported.<sup><xref ref-type="bibr" rid="bibr53-0003319711416804">53</xref>,<xref ref-type="bibr" rid="bibr55-0003319711416804">55</xref>,<xref ref-type="bibr" rid="bibr56-0003319711416804">56</xref>,<xref ref-type="bibr" rid="bibr60-0003319711416804">60</xref>,<xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref>,<xref ref-type="bibr" rid="bibr73-0003319711416804">73</xref></sup> The most common problems were barotraumatic otitis,<sup><xref ref-type="bibr" rid="bibr53-0003319711416804">53</xref>,<xref ref-type="bibr" rid="bibr55-0003319711416804">55</xref>,<xref ref-type="bibr" rid="bibr56-0003319711416804">56</xref>,<xref ref-type="bibr" rid="bibr60-0003319711416804">60</xref>,<xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref>,<xref ref-type="bibr" rid="bibr73-0003319711416804">73</xref></sup> pain in the ears that required myringotomy,<sup><xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref></sup> tympanic rupture,<sup><xref ref-type="bibr" rid="bibr73-0003319711416804">73</xref></sup> and cataract.<sup><xref ref-type="bibr" rid="bibr55-0003319711416804">55</xref>,<xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref></sup> Löndahl et al<sup><xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref></sup> reported side effects including hypoglycemia, treatment-related dizziness, and minor head injury due to transient loss of consciousness, which were, however, present in both HBO and placebo groups. During HBO sessions, there have been some fatal events,<sup><xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref>,<xref ref-type="bibr" rid="bibr87-0003319711416804">87</xref>,<xref ref-type="bibr" rid="bibr88-0003319711416804">88</xref></sup> but it has not been clarified whether they were related to HBO therapy or to the severe comorbidities. Importantly, oxygen toxicity, seizures, or pneumothorax have not been seen.<sup><xref ref-type="bibr" rid="bibr53-0003319711416804">53</xref>,<xref ref-type="bibr" rid="bibr55-0003319711416804">55</xref>,<xref ref-type="bibr" rid="bibr56-0003319711416804">56</xref>,<xref ref-type="bibr" rid="bibr60-0003319711416804">60</xref>,<xref ref-type="bibr" rid="bibr62-0003319711416804">62</xref>,<xref ref-type="bibr" rid="bibr73-0003319711416804">73</xref>,<xref ref-type="bibr" rid="bibr87-0003319711416804">87</xref>,<xref ref-type="bibr" rid="bibr88-0003319711416804">88</xref></sup> In theory, deterioration of diabetic retinopathy could occur during HBO therapy, but this has hitherto not been reported.<sup><xref ref-type="bibr" rid="bibr7-0003319711416804">7</xref></sup>
</p>
</sec>
<sec id="section14-0003319711416804">
<title>Cost</title>
<p>HBO leads to a precipitous increase in treatment cost, which has been identified as a major disadvantage prohibiting wide use.<sup><xref ref-type="bibr" rid="bibr89-0003319711416804">89</xref></sup> Nonetheless, cost of HBO therapy may vary from country to country because of the different methods of health care.<sup><xref ref-type="bibr" rid="bibr7-0003319711416804">7</xref></sup> Hyperbaric oxygen facilities are available in a minority of communities, thus the acquisition cost for a monoplace hyperbaric chamber and associated facility remodeling is $400 000, while that of a multiplace chamber may have initial capital costs of millions of dollars. Moreover, all chambers require trained staff, which should be taken into the account of operational costs.<sup><xref ref-type="bibr" rid="bibr6-0003319711416804">6</xref></sup> Each course of treatment costs $1 200 089, while 30-session protocol costs have a wide spectrum of values ($9000,<sup><xref ref-type="bibr" rid="bibr90-0003319711416804">90</xref></sup> $20 000,<sup><xref ref-type="bibr" rid="bibr6-0003319711416804">6</xref></sup> $50 000 [Medicare], and $200 000 [private payments]<sup><xref ref-type="bibr" rid="bibr60-0003319711416804">60</xref></sup>). Total cost for treating all grade III ulcers has been estimated in the range of $252 to $984 million in the United States.<sup><xref ref-type="bibr" rid="bibr89-0003319711416804">89</xref></sup> Additional variables increasing cost include patient transfer to specialized HBO units and the time-consuming nature of HBO sessions, which result in increased loss of working hours.</p>
<p>These expenses, however, should be viewed in light of the total cost associated with therapeutic failure: the cost for osteomyelitis, amputation, and subsequent rehabilitation. The available numbers are staggering, while podiatric medical care can reduce the disease and economic burdens of diabetes.<sup><xref ref-type="bibr" rid="bibr91-0003319711416804">91</xref></sup> Generally, management of diabetic foot ulcers costs health care an average of $14 400 per episode<sup><xref ref-type="bibr" rid="bibr90-0003319711416804">90</xref></sup> and annually $5 billion in the United States<sup><xref ref-type="bibr" rid="bibr59-0003319711416804">59</xref></sup> and £225 million in the United Kingdom.<sup><xref ref-type="bibr" rid="bibr92-0003319711416804">92</xref></sup> The cost for pedal amputation, additional to standard ulcer care and any surgical and antibiotic intervention, ranges from $18 760 to more than $40 000 per case,<sup><xref ref-type="bibr" rid="bibr6-0003319711416804">6</xref>,<xref ref-type="bibr" rid="bibr90-0003319711416804">90</xref></sup> while the rehabilitation expenses range from $40 000 to $50 000 per case.<sup><xref ref-type="bibr" rid="bibr90-0003319711416804">90</xref></sup> The total cost of the diabetic foot in the United States in 2007 was estimated to be $30 billion, of which $19 billion was due to foot ulceration and $11 billion to amputations.<sup><xref ref-type="bibr" rid="bibr64-0003319711416804">64</xref></sup>
</p>
<p>In a more comprehensive analysis, the cost-effectiveness of add-on HBO has been estimated by the incremental cost per additional quality-adjusted life year (QALY). In the United States, this was $27 310 at the first year, $5166 after 5 years, and $2255 after 12 years.<sup><xref ref-type="bibr" rid="bibr93-0003319711416804">93</xref>,<xref ref-type="bibr" rid="bibr94-0003319711416804">94</xref></sup> In Canada, it was CND$9091 after 12 years.<sup><xref ref-type="bibr" rid="bibr95-0003319711416804">95</xref></sup> Given the high direct medical cost of a major amputation and subsequent participant rehabilitation, it must be emphasized that HBO may, finally, lower the cost of care for diabetic nonhealing wounds in the first year of therapy.<sup><xref ref-type="bibr" rid="bibr6-0003319711416804">6</xref></sup> Hence, although comprehensive economic analyses are sparse, HBO is potentially cost-effective<sup><xref ref-type="bibr" rid="bibr93-0003319711416804">93</xref><xref ref-type="bibr" rid="bibr94-0003319711416804"/>–<xref ref-type="bibr" rid="bibr95-0003319711416804">95</xref></sup> or even cost-saving.<sup><xref ref-type="bibr" rid="bibr57-0003319711416804">57</xref>,<xref ref-type="bibr" rid="bibr66-0003319711416804">66</xref></sup>
</p>
</sec>
</sec>
</sec>
<sec id="section15-0003319711416804">
<title>Topical “Hyperbaric” Oxygen Treatment</title>
<p>Topical application of “hyperbaric” oxygen has also been investigated. Topical oxygen is introduced into an airtight chamber or polyethylene bag, sealed around a limb or the trunk either by a tourniquet device or by tape and high-flow oxygen, with pressures just over 1.0 ATA. This is the reason why the Undersea and Hyperbaric Medical Society declares that the term “hyperbaric” should not be used to characterize this kind of treatment, taking also into consideration that this treatment modality is not based on the aforementioned mechanisms of systemic HBO.<sup><xref ref-type="bibr" rid="bibr96-0003319711416804">96</xref></sup> Currently, the available data come only from rather small nonrandomized studies. These have suggested that topical HBO may exert some favorable action on the healing process, when applied alone<sup><xref ref-type="bibr" rid="bibr97-0003319711416804">97</xref></sup> or in collaboration with a laser.<sup><xref ref-type="bibr" rid="bibr98-0003319711416804">98</xref><xref ref-type="bibr" rid="bibr99-0003319711416804"/>–<xref ref-type="bibr" rid="bibr100-0003319711416804">100</xref></sup> The 2 published randomized controlled trials, however, reported controversial results.<sup><xref ref-type="bibr" rid="bibr101-0003319711416804">101</xref>,<xref ref-type="bibr" rid="bibr102-0003319711416804">102</xref></sup> Accordingly, there is a lot more to learn regarding the potential contribution of topical HBO to the treatment of diabetic foot ulcers.</p>
</sec>
<sec id="section16-0003319711416804">
<title>Important Considerations</title>
<p>The lack of unanimity in results from clinical trials raises the following questions:<list list-type="order">
<list-item>
<p>Which is the most sensitive technique to assess lower-extremity ischemia?</p>
</list-item>
<list-item>
<p>Which are the characteristics of patients who are most likely to benefit from HBO therapy?</p>
</list-item>
<list-item>
<p>Which patients are unlikely to gain from HBO?</p>
</list-item>
<list-item>
<p>Which “dose” of HBO yields best results?</p>
</list-item>
<list-item>
<p>Are there any recent recommendations from international organizations?</p>
</list-item>
</list>
</p>
<sec id="section17-0003319711416804">
<title>Screening Techniques</title>
<p>There is a variety of techniques to measure tissue hypoxia. Invasive (direct measurement of tissue partial oxygen pressure) or imaging modalities (duplex ultrasonography, Doppler flowmetry, arteriography, magnetic resonance imaging [MRI] techniques, positron emission tomography [PET] scan, and near infrared reflectance spectroscopy), as well as transcutaneous O<sub>2</sub> and CO<sub>2</sub> pressure measurement offer information on microvascular function. Transcutaneous oxygen pressure (TcPO<sub>2</sub>) reflects micro- and macrocirculation and is recommended for assessment of the diabetic foot at risk and selection of patients suitable for HBO.<sup><xref ref-type="bibr" rid="bibr103-0003319711416804">103</xref><xref ref-type="bibr" rid="bibr104-0003319711416804"/>–<xref ref-type="bibr" rid="bibr105-0003319711416804">105</xref></sup> Parameters that could influence TcPO<sub>2</sub> measurement include electrode localization, skin thickness, and skin oxygen consumption, skin ointments, presence of edema, skin heating, and variation in respiratory or cardiac condition.<sup><xref ref-type="bibr" rid="bibr105-0003319711416804">105</xref></sup> Other noninvasive indices of large vessel function, such as arterial toe blood pressure (TBP) and ankle–brachial index (ABI), have also been used. Faglia et al<sup><xref ref-type="bibr" rid="bibr53-0003319711416804">53</xref></sup> reported an association of reduced ABI with increased risk of major amputation in a randomized study. These results, however, were not confirmed by Löndahl et al<sup><xref ref-type="bibr" rid="bibr105-0003319711416804">105</xref></sup> and Fife et al,<sup><xref ref-type="bibr" rid="bibr88-0003319711416804">88</xref></sup> who found no correlation between healing of diabetic foot ulcer and ABI in larger patient series. Finally, there is evidence that TBP is not a reliable tool for predicting major amputation or ulcer healing.<sup><xref ref-type="bibr" rid="bibr55-0003319711416804">55</xref>,<xref ref-type="bibr" rid="bibr105-0003319711416804">105</xref></sup>
</p>
</sec>
<sec id="section18-0003319711416804">
<title>Characteristics of the Patients Who are Most Likely to Benefit From HBO Therapy</title>
<p>Before referral for HBO therapy, a patient should have failed to improve on conventional treatment.<sup><xref ref-type="bibr" rid="bibr6-0003319711416804">6</xref></sup> Potential candidates for HBO treatment usually have Wagner III, IV, V lesions.<sup><xref ref-type="bibr" rid="bibr7-0003319711416804">7</xref></sup> The greatest benefit of HBO therapy is achieved in those with intact or little compromised arterial supply. In such participants, tissue nutritive flow and oxygen supply are only compromised by local injury or infection.<sup><xref ref-type="bibr" rid="bibr19-0003319711416804">19</xref></sup> Sufficient healing with HBO treatment is still achieved in cases with impaired peripheral circulation, but this can only be achieved as a part of a coordinated medical–surgical approach.<sup><xref ref-type="bibr" rid="bibr19-0003319711416804">19</xref></sup> Bearing this in mind, a vascular consultation with revascularization if appropriate should be offered before HBO.<sup><xref ref-type="bibr" rid="bibr6-0003319711416804">6</xref></sup> Transcutaneous oxygen pressure has emerged as the most reliable tool predicting the outcome of HBO therapy: critical values are presented in <xref ref-type="table" rid="table4-0003319711416804">Table 4</xref>
.<sup><xref ref-type="bibr" rid="bibr69-0003319711416804">69</xref>,<xref ref-type="bibr" rid="bibr86-0003319711416804">86</xref>,<xref ref-type="bibr" rid="bibr105-0003319711416804">105</xref><xref ref-type="bibr" rid="bibr106-0003319711416804"/><xref ref-type="bibr" rid="bibr107-0003319711416804"/>–<xref ref-type="bibr" rid="bibr108-0003319711416804">108</xref></sup> In general, HBO is used when ankle pressure is about 40 mm Hg<sup><xref ref-type="bibr" rid="bibr109-0003319711416804">109</xref></sup> and periwound TcPO<sub>2</sub> is less than 40 mm Hg in normobaric air (indicating tissue ischemia) but increases more than 10 mm Hg in normobaric 100% O<sub>2</sub> and more than 200 mm Hg in the hyperbaric chamber.<sup><xref ref-type="bibr" rid="bibr75-0003319711416804">75</xref></sup>
</p>
<table-wrap id="table4-0003319711416804" position="float">
<label>Table 4.</label>
<caption>
<p>Studies That Present the Critical Values of TcPO2 That Could Predict the Outcome of HBO Therapy</p>
</caption>
<graphic alternate-form-of="table4-0003319711416804" xlink:href="10.1177_0003319711416804-table4.tif"/>
<table>
<thead>
<tr>
<th align="center" colspan="5">Study Characteristics</th>
<th align="center" colspan="3">TcPO<sub>2</sub> (mm Hg) / Success (%)</th>
<th align="center" colspan="3">TcPO<sub>2</sub> (mm Hg)/Failure (%)</th>
</tr>
<tr>
<th>Study</th>
<th>Type</th>
<th>HBO</th>
<th>Participants</th>
<th>TcPO<sub>2</sub>
</th>
<th>Normobaric air</th>
<th>Normobaric O2</th>
<th>HBO</th>
<th>Normobaric air</th>
<th>Normobaric O<sub>2</sub>
</th>
<th>HBO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wattel et al<sup><xref ref-type="bibr" rid="bibr69-0003319711416804">69</xref></sup>
</td>
<td>CS</td>
<td>2.5 ATA × 90 min × 2/d</td>
<td>11 DM-9 I</td>
<td>
</td>
<td>&gt;100/100</td>
<td>
</td>
<td>
</td>
<td>&lt;100/100</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>Glorman et al<sup><xref ref-type="bibr" rid="bibr106-0003319711416804">106</xref></sup>
</td>
<td>PS NR UC</td>
<td>2-2.5 ATA</td>
<td>36 CI</td>
<td>
</td>
<td colspan="2">↑ &gt;10/70 ↑&lt;10/11</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td rowspan="2">Fife et al<sup><xref ref-type="bibr" rid="bibr87-0003319711416804">87</xref></sup>
</td>
<td rowspan="2">RS</td>
<td rowspan="2">2-2.4 ATA</td>
<td rowspan="2">1144 DM</td>
<td rowspan="2">44°C</td>
<td rowspan="2">≥25 NPV</td>
<td rowspan="2">25-30 (69% RL)</td>
<td rowspan="2">&gt;200 (74% RL)</td>
<td>
</td>
<td>&lt;35/41(69%AC)</td>
<td>
</td>
</tr>
<tr>
<td colspan="3">&lt;15 in air + &lt;400 in HBO (75.8%RL, 73.3%PPV)</td>
</tr>
<tr>
<td rowspan="2">Zgonis et al<sup><xref ref-type="bibr" rid="bibr86-0003319711416804">86</xref></sup>
</td>
<td rowspan="2">RS</td>
<td rowspan="2">2 ATA × 2 h</td>
<td rowspan="2">35 DM 40 feet TcPO<sub>2</sub> &lt;40 postpartial amputation</td>
<td rowspan="2">34°C</td>
<td>PO mean 24</td>
<td rowspan="2">
</td>
<td rowspan="2">
</td>
<td rowspan="2">PO mean 11</td>
<td rowspan="2">
</td>
<td rowspan="2">
</td>
</tr>
<tr>
<td>&lt;29/100</td>
</tr>
<tr>
<td rowspan="2">Oubre et al<sup><xref ref-type="bibr" rid="bibr107-0003319711416804">107</xref></sup>
</td>
<td rowspan="2">RS</td>
<td rowspan="2">2.5 ATA × 90 min × 6 w</td>
<td rowspan="2">73 patients 37 diabetics 85 ulcers</td>
<td rowspan="2">
</td>
<td>Mean 57/36 (maximum)</td>
<td rowspan="2">
</td>
<td rowspan="2">
</td>
<td rowspan="2">Mean 38/24</td>
<td rowspan="2">
</td>
<td rowspan="2">
</td>
</tr>
<tr>
<td>Mean 44/38 (minimum)</td>
</tr>
<tr>
<td rowspan="3">Fife et al<sup><xref ref-type="bibr" rid="bibr108-0003319711416804">108</xref></sup>
</td>
<td rowspan="3">Cons</td>
<td rowspan="3">
</td>
<td rowspan="3">
</td>
<td rowspan="3">
</td>
<td>&lt;30 CI</td>
<td rowspan="3">&gt;100 no vascular disease</td>
<td rowspan="3">
</td>
<td rowspan="3">
</td>
<td rowspan="3">↑&lt;10/68 postamputation</td>
<td rowspan="3">
</td>
</tr>
<tr>
<td>&lt;40 tissue hypoxia</td>
</tr>
<tr>
<td>Postrevascularization ↑ &gt;40</td>
</tr>
<tr>
<td rowspan="3">Löndahl et al<sup><xref ref-type="bibr" rid="bibr105-0003319711416804">105</xref></sup>
</td>
<td rowspan="3">PS R C</td>
<td rowspan="3">TcPO<sub>2</sub> &gt;25mm Hg →HBO</td>
<td rowspan="3">38 HBO 37 air</td>
<td rowspan="3">42°C</td>
<td>&gt;75/100</td>
<td>&gt;200/75</td>
<td rowspan="3">
</td>
<td rowspan="3">&lt;25/100</td>
<td rowspan="3">&lt;50/100</td>
<td rowspan="3">
</td>
</tr>
<tr>
<td>26-50/50</td>
<td>51-100/25</td>
</tr>
<tr>
<td>51-75/73</td>
<td>101-200/70</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0003319711416804">
<p>Abbreviations: HBO, hyperbaric oxygen; TcPO<sub>2</sub>, transcutaneous oxymetry; temp., temperature; CS, case series; ATA, atmosphere absolute; min, minutes; DM, diabetes mellitus with foot ulcers; I, ischemia; PS, prospective; NR, nonrandomized; UC, uncontrolled; CI, critical ischemia; ↑, increase; RS, retrospective; NPV, nonpredictive value; RL, reliability; AC, accuracy; PPV, positive predictive value h, hours; PO, preoperative; w, weeks; Cons, consensus; R, randomized; C, controlled.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section19-0003319711416804">
<title>Characteristics of Patients in Whom HBO Therapy is Unlikely to be Effective</title>
<p>Hyperbaric oxygen treatment is unlikely to be effective in patients with unfavorable TcPO<sub>2</sub> values (<xref ref-type="table" rid="table4-0003319711416804">Table 4</xref>
).<sup><xref ref-type="bibr" rid="bibr69-0003319711416804">69</xref>,<xref ref-type="bibr" rid="bibr86-0003319711416804">86</xref>,<xref ref-type="bibr" rid="bibr105-0003319711416804">105</xref><xref ref-type="bibr" rid="bibr106-0003319711416804"/><xref ref-type="bibr" rid="bibr107-0003319711416804"/>–<xref ref-type="bibr" rid="bibr108-0003319711416804">108</xref></sup> This also holds true for very old patients, with history of smoking,<sup><xref ref-type="bibr" rid="bibr107-0003319711416804">107</xref></sup> renal failure, and high Wagner scores.<sup><xref ref-type="bibr" rid="bibr88-0003319711416804">88</xref></sup> Furthermore, wounds exhibiting impaired growth factor production, low chemotactic responsiveness, or normal levels of tissue oxygenation are not appropriate for HBO therapy.<sup><xref ref-type="bibr" rid="bibr110-0003319711416804">110</xref></sup> All wounds must be off-loaded during HBO treatment, while failure to do so seriously undermines treatment efficacy.</p>
</sec>
<sec id="section20-0003319711416804">
<title>“Dose” of HBO</title>
<p>Oxygen pressure in the chamber with 100% O<sub>2</sub> is usually 2 to 2.5 ATA. The greatest benefit of HBO treatment appears to occur with the first 15 treatments<sup><xref ref-type="bibr" rid="bibr88-0003319711416804">88</xref></sup> and is usually continued for at least 30 days, which according to the Center for Medicare and Medicaid Services is the minimum duration required to characterize an ulcer as healed.<sup><xref ref-type="bibr" rid="bibr6-0003319711416804">6</xref></sup> A scheme of 5 to 7 days of treatment per week including a rest period between treatments is followed, while each session is performed once a day and lasts no more than 90 minutes.<sup><xref ref-type="bibr" rid="bibr109-0003319711416804">109</xref></sup> It should be mentioned that HBO is applied in a uniform fashion to all patients, regardless of their individual needs, raising the question whether personalized HBO therapy should be pursued to yield even better results. In the event of excessive dose, the massive increase in tissue PO<sub>2</sub> results in oxygen toxicity.<sup><xref ref-type="bibr" rid="bibr21-0003319711416804">21</xref></sup>
</p>
</sec>
<sec id="section21-0003319711416804">
<title>Recommendations From International Organizations</title>
<p>Scientific associations and governmental agencies are increasingly appreciating the value of add-on HBO in the treatment of the diabetic foot.<sup><xref ref-type="bibr" rid="bibr111-0003319711416804">111</xref></sup> In 1998, the recommendations of the Fourth European Consensus Conference on Hyperbaric Medicine and HBO in the management of diabetic foot lesions, which was supported by the British Hyperbaric Association, characterized diabetic patients with ischemic, limb-threatening, Wagner grade III, IV, V lesions failing to respond on standard treatment as potential candidates for HBO.<sup><xref ref-type="bibr" rid="bibr112-0003319711416804">112</xref></sup> In 1999, the American Diabetes Association endorsed the use of adjunctive HBO in severe ischemic diabetic foot lesions refractory to standard care.<sup><xref ref-type="bibr" rid="bibr113-0003319711416804">113</xref></sup> The CMS has recognized and agreed to reimburse HBO in addition to standard treatment of diabetic patients with foot lesions Wagner grade ≥III, which have not healed after at least 30 days of standard treatment.<sup><xref ref-type="bibr" rid="bibr114-0003319711416804">114</xref></sup> Blue Cross Blue Shield,<sup><xref ref-type="bibr" rid="bibr115-0003319711416804">115</xref></sup> Australian Medicare Service Advisory Committee,<sup><xref ref-type="bibr" rid="bibr116-0003319711416804">116</xref></sup> Canadian Diabetes Association,<sup><xref ref-type="bibr" rid="bibr117-0003319711416804">117</xref></sup> and Wound Healing Society<sup><xref ref-type="bibr" rid="bibr118-0003319711416804">118</xref></sup> have similar guidelines. In 2009, according to Oxford and Centers for Medicare &amp; Medicaid Services (CMS) policies, systemic but not topical HBO therapy should be administered as mentioned above.<sup><xref ref-type="bibr" rid="bibr119-0003319711416804">119</xref></sup> Recently, the Consensus Recommendations on Advancing the Standard of Care for Treating Neuropathic Foot Ulcers in Patients with Diabetes has adopted these guidelines and proposed to offer HBO in persistently ischemic or infected diabetic foot ulcers with recalcitrant osteomyelitis and progressive necrotizing infection in addition to standard treatment.<sup><xref ref-type="bibr" rid="bibr120-0003319711416804">120</xref></sup> Periwound TcPO<sub>2</sub> is proposed as a screening method: TcPO<sub>2</sub> = 30 mm Hg denotes critical limb ischemia, while HBO should be administered when the normobaric TcPO<sub>2</sub> &lt;50 mm Hg and hyperbaric TcPO<sub>2</sub> = 200 mm Hg).<sup><xref ref-type="bibr" rid="bibr120-0003319711416804">120</xref></sup>
</p>
</sec>
</sec>
<sec id="section22-0003319711416804">
<title>Conclusions–Implications for Future Research</title>
<p>Given the magnitude of the health concern associated with the diabetic foot worldwide, alternative and/or add-on therapies are essential.<sup><xref ref-type="bibr" rid="bibr1-0003319711416804">1</xref><xref ref-type="bibr" rid="bibr2-0003319711416804"/><xref ref-type="bibr" rid="bibr3-0003319711416804"/>–<xref ref-type="bibr" rid="bibr4-0003319711416804">4</xref></sup> Hyperbaric oxygen is a very useful therapeutic modality. It improves tissue hypoxia, reduces inflammation, limits infection, and promotes fibroblast proliferation, collagen production, and angiogenesis. Hence, it seems to be the ideal candidate for an add-on therapy directed at persistent ischemic diabetic foot ulcers Wagner grade &gt; II.<sup><xref ref-type="bibr" rid="bibr121-0003319711416804">121</xref></sup>
</p>
<p>The impact of HBO treatment on ulcer healing and amputation rates has been investigated, initially, in small, nonrandomized studies and, more recently, in larger double-blind, randomized controlled trials. Accumulating data is encouraging and suggests that HBO reduces amputation rates, increases the likelihood of healing in infected diabetic foot ulcers, and improves quality of life. The recently published results of the HODFU study have lent further support to this view and indicated that HBO may even improve patient survival at 3 years.<sup><xref ref-type="bibr" rid="bibr122-0003319711416804">122</xref></sup> There is also evidence that results could be further improved by adding <italic>N</italic>-acetylcysteine<sup><xref ref-type="bibr" rid="bibr123-0003319711416804">123</xref></sup> and basic fibroblast growth factor.<sup><xref ref-type="bibr" rid="bibr124-0003319711416804">124</xref></sup> Impressively, pretreatment with HBO may also improve the success rates of skin grafting.<sup><xref ref-type="bibr" rid="bibr125-0003319711416804">125</xref>,<xref ref-type="bibr" rid="bibr126-0003319711416804">126</xref></sup>
</p>
<p>These advantageous effects notwithstanding, some issues deserve attention. Hyperbaric oxygen remains extremely expensive and is only available in very few specialized centers. Although there is evidence favoring cost-effectiveness, there is an urgent need for further economic analysis. Moreover, HBO treatment may have untoward effects. While no major adverse events have hitherto been reported in diabetic foot patients, more information is required.</p>
<p>A further important issue is study limitations. First, inconsistent methodology has been applied, as manifested by the considerable differences in patient population, ulcer etiology (neuropathic vs neuroischemic), severity (Wagner or UT classification), ulcer duration and location, as well as in selection criteria (TcPO<sub>2</sub>, ABI, and TPO) and treatment schedules (oxygen pressure, daily session duration, and mean number of treatment). While some heterogeneity is inevitable, a more universally accepted HBO regime is desirable to enable the production of guidelines. Second, the vast majority of data originate from either nonrandomized or randomized but not double-blind trials, seriously undermining their level of evidence. Accordingly, we need larger, more reliable trials based on common grounds. Hopefully, data will soon be available by the study groups of COST B14<sup><xref ref-type="bibr" rid="bibr127-0003319711416804">127</xref></sup> and O’Reilly,<sup><xref ref-type="bibr" rid="bibr128-0003319711416804">128</xref></sup> shedding more light on the effectiveness of HBO in clinical practice.</p>
<p>Appropriate patient selection is of paramount importance to fulfill the expectations of HBO therapy. At the same time, patients who are unlikely to benefit or who may exhibit toxicity should be avoided. Thus far, guidelines suggest add-on HBO therapy for diabetic patients with ischemic foot lesions Wagner ≥grade III, which have failed an adequate course of at least 30 days of standard wound therapy.<sup><xref ref-type="bibr" rid="bibr114-0003319711416804">114</xref></sup> Using periwound TcPO<sub>2</sub> as a criterion, HBO should be administered when normobaric TcPO<sub>2</sub> &lt;50 mm Hg and hyperbaric TcPO<sub>2</sub> = 200 mm Hg.<sup><xref ref-type="bibr" rid="bibr120-0003319711416804">120</xref></sup>
</p>
<p>Obviously, there is a very long way to go before the broad implementation of HBO in the routine clinical care of the diabetic foot. At the moment, this modality is not indicated for the management of the vast majority of diabetic foot ulcers. Conversely, HBO may be helpful in persistent, ischemic, or neuroischemic, infected diabetic foot ulcers with recalcitrant osteomyelitis and progressive necrotizing infection in addition to standard treatment, especially when revascularization is not feasible. Results from ongoing trials employing more stringent criteria are anticipated to help toward a better appreciation of HBO. Until then, we must not be oblivious to the fact that available facilities and expertise must be ardently employed to improve the grim fate of the diabetic foot.<sup><xref ref-type="bibr" rid="bibr129-0003319711416804">129</xref>,<xref ref-type="bibr" rid="bibr130-0003319711416804">130</xref></sup>
</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319711416804">
<p>The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr N. Papanas has been an advisory board member of Miro; has participated in sponsored studies by Novo Nordisk and Novartis; received honoraria as a speaker for Novo Nordisk and Pfizer; and attended conferences sponsored by Miro, Novo Nordisk, Sanofi-Aventis, and Pfizer. Professor E. Maltezos has participated in sponsored studies by Novo Nordisk and Novartis and attended conferences sponsored by Wyeth, Pfizer, and Bayer.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319711416804">
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711416804">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunt</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Diabetes: foot ulcers and amputations</article-title>. <source>Clin Evid (Online)</source>. <year>2009</year>;<volume>1</volume>(<issue>2</issue>):<fpage>602</fpage>.</citation>
</ref>
<ref id="bibr2-0003319711416804">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papanas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Maltezos</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>The diabetic foot: established and emerging treatments</article-title>. <source>Acta Clin Belg</source>. <year>2007</year>;<volume>62</volume>(<issue>4</issue>):<fpage>230</fpage>–<lpage>238</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711416804">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papanas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Maltezos</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Advances in treating the ischaemic diabetic foot</article-title>. <source>Curr Vasc Pharmacol</source>. <year>2008</year>;<volume>6</volume>(<issue>1</issue>):<fpage>23</fpage>–<lpage>28</lpage>.</citation>
</ref>
<ref id="bibr4-0003319711416804">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boulton</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>The diabetic foot: grand overview, epidemiology and pathogenesis</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2008</year>;<volume>24</volume>(<issue>suppl 1</issue>):<fpage>S3</fpage>–<lpage>S6</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711416804">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frykberg</surname>
<given-names>RG</given-names>
</name>
</person-group>. <article-title>Diabetic foot ulcers: pathogenesis and management</article-title>. <source>Am Fam Physician</source>. <year>2002</year>;<volume>66</volume>(<issue>9</issue>):<fpage>1655</fpage>–<lpage>1662</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711416804">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>RC</given-names>
</name>
</person-group>. <article-title>Point: hyperbaric oxygen is beneficial for diabetic foot wounds</article-title>. <source>Clin Infect Dis</source>. <year>2006</year>;<volume>43</volume>(<issue>2</issue>):<fpage>188</fpage>–<lpage>192</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711416804">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bakker</surname>
<given-names>DJ</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen therapy and the diabetic foot</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2000</year>;<volume>16</volume>(<issue>suppl 1</issue>):<fpage>S55</fpage>–<lpage>S58</lpage>.</citation>
</ref>
<ref id="bibr8-0003319711416804">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gul</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Basit</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Ahmadani</surname>
<given-names>MY</given-names>
</name>
<name>
<surname>Miyan</surname>
<given-names>Z</given-names>
</name>
</person-group>. <article-title>Role of wound classification in predicting the outcome of diabetic foot ulcer</article-title>. <source>J Pak Med Assoc</source>. <year>2006</year>;<volume>56</volume>(<issue>10</issue>):<fpage>444</fpage>–<lpage>447</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711416804">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parisi</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Zantut-Wittmann</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Pavin</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Machado</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nery</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jeffcoate</surname>
<given-names>WJ</given-names>
</name>
</person-group>. <article-title>Comparison of three systems of classification in predicting the outcome of diabetic foot ulcers in a Brazilian population</article-title>. <source>Eur J Endocrinol</source>. <year>2008</year>;<volume>159</volume>(<issue>4</issue>):<fpage>417</fpage>–<lpage>422</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711416804">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papanas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Maltezos</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Growth factors in the treatment of diabetic foot ulcers: new technologies, any promises?</article-title> <source>Int J Low Extrem Wounds</source>. <year>2007</year>;<volume>6</volume>(<issue>1</issue>):<fpage>37</fpage>–<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711416804">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hankey</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Norman</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Eikelboom</surname>
<given-names>JW</given-names>
</name>
</person-group>. <article-title>Medical treatment of peripheral arterial disease</article-title>. <source>JAMA</source>. <year>2006</year>;<volume>295</volume>(<issue>5</issue>):<fpage>547</fpage>–<lpage>553</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711416804">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daskalopoulou</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>Lipid-lowering therapy in patients with peripheral arterial disease</article-title>. <source>J Cardiovasc Pharmacol Ther</source>. <year>2005</year>;<volume>10</volume>(<issue>1</issue>):<fpage>145</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr13-0003319711416804">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alnaeb</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Alobaid</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Seifalian</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Statins and peripheral arterial disease: potential mechanisms and clinical benefits</article-title>. <source>Ann Vasc Surg</source>. <year>2006</year>;<volume>20</volume>(<issue>5</issue>):<fpage>696</fpage>–<lpage>705</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711416804">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paraskevas</surname>
<given-names>KI</given-names>
</name>
<name>
<surname>Athyros</surname>
<given-names>VG</given-names>
</name>
<name>
<surname>Briana</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Kakafika</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Karagiannis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures</article-title>. <source>Curr Drug Targets</source>. <year>2007</year>;<volume>8</volume>(<issue>8</issue>):<fpage>942</fpage>–<lpage>951</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711416804">
<label>15</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name>
<surname>Hampson</surname>
<given-names>NB</given-names>
</name>
</person-group> ed. <source>Hyperbaric Oxygen Therapy: 1999 Committee report</source>. <publisher-loc>Kensington, MD</publisher-loc>: <publisher-name>Undersea and Hyperbaric Medical Society</publisher-name>; <year>1999</year>.</citation>
</ref>
<ref id="bibr16-0003319711416804">
<label>16</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Henshaw</surname>
<given-names>N</given-names>
</name>
</person-group>. <source>Aero-Chalinos</source>. <publisher-loc>Dublin</publisher-loc>: <publisher-name>Dancer</publisher-name>; <year>1664</year>.</citation>
</ref>
<ref id="bibr17-0003319711416804">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schwaitzberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Berliner</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Zarin</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen for treating wounds: a systematic review of the literature</article-title>. <source>Arch Surg</source>. <year>2003</year>;<volume>138</volume>(<issue>3</issue>):<fpage>272</fpage>–<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr18-0003319711416804">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gill</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>CN</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen: its uses, mechanisms of action and outcomes</article-title>. <source>QJM</source>. <year>2004</year>;<volume>97</volume>(<issue>7</issue>):<fpage>385</fpage>–<lpage>395</lpage>.</citation>
</ref>
<ref id="bibr19-0003319711416804">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niinikoski</surname>
<given-names>JH</given-names>
</name>
</person-group>. <article-title>Clinical hyperbaric oxygen therapy, wound perfusion, and transcutaneous oximetry</article-title>. <source>World J Surg</source>. <year>2004</year>;<volume>28</volume>(<issue>3</issue>):<fpage>307</fpage>–<lpage>311</lpage>.</citation>
</ref>
<ref id="bibr20-0003319711416804">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Felix</surname>
<given-names>FN</given-names>
</name>
<name>
<surname>Woodley</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Shim</surname>
<given-names>EK</given-names>
</name>
</person-group>. <article-title>The role of oxygen in wound healing: a review of the literature</article-title>. <source>Dermatol Surg</source>. <year>2008</year>;<volume>34</volume>(<issue>9</issue>):<fpage>1159</fpage>–<lpage>1169</lpage>.</citation>
</ref>
<ref id="bibr21-0003319711416804">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sen</surname>
<given-names>CK</given-names>
</name>
</person-group>. <article-title>Wound healing essentials: let there be oxygen</article-title>. <source>Wound Repair Regen</source>. <year>2009</year>;<volume>17</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr22-0003319711416804">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsunami</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yukawa</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Antioxidant status and lipid peroxidation in diabetic rats under hyperbaric oxygen exposure</article-title>. <source>Physiol Res</source>. <year>2010</year>;<volume>59</volume>(<issue>1</issue>):<fpage>97</fpage>–<lpage>104</lpage>.</citation>
</ref>
<ref id="bibr23-0003319711416804">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roeckl-Wiedmann</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kranke</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Systematic review of hyperbaric oxygen in the management of chronic wounds</article-title>. <source>Br J Surg</source>. <year>2005</year>;<volume>92</volume>(<issue>1</issue>):<fpage>24</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr24-0003319711416804">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cimşit</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Uzun</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yildiz</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen therapy as an anti-infective agent</article-title>. <source>Expert Rev Anti Infect Ther</source>. <year>2009</year>;<volume>7</volume>(<issue>8</issue>):<fpage>1015</fpage>–<lpage>1026</lpage>.</citation>
</ref>
<ref id="bibr25-0003319711416804">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koomanachai</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Keel</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Johnson-Arbor</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Suecof</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Nicolau</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Kuti</surname>
<given-names>JL</given-names>
</name>
</person-group>. <article-title>Linezolid penetration into wound tissue of two diabetic patients before and after hyperbaric oxygen therapy</article-title>. <source>Undersea Hyperb Med</source>. <year>2011</year>;<volume>38</volume>(<issue>1</issue>):<fpage>11</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr26-0003319711416804">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thom</surname>
<given-names>SR</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen: its mechanisms and efficacy</article-title>. <source>Plast Reconstr Surg</source>. <year>2011</year>;<volume>127</volume>(<issue>suppl</issue>):<fpage>S131</fpage>.</citation>
</ref>
<ref id="bibr27-0003319711416804">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsunami</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Enhancement of reactive oxygen species and induction of apoptosis in streptozotocin-induced diabetic rats under hyperbaric oxygen exposure</article-title>. <source>Int J Clin Exp Pathol</source>. <year>2011</year>;<volume>4</volume>(<issue>3</issue>):<fpage>255</fpage>–<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr28-0003319711416804">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gürdöl</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cimşit</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Oner-Iyidoğan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Körpinar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yalçinkaya</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Koçak</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Early and late effects of hyperbaric oxygen treatment on oxidative stress parameters in diabetic patients</article-title>. <source>Physiol Res</source>. <year>2008</year>;<volume>57</volume>(<issue>1</issue>):<fpage>41</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr29-0003319711416804">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gurdol</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cimsit</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Oner-Iyidogan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kocak</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sengun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yalcinkaya-Demirsoz</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Collagen synthesis, nitric oxide and asymmetric dimethylarginine in diabetic subjects undergoing hyperbaric oxygen therapy</article-title>. <source>Physiol Res</source>. <year>2010</year>;<volume>59</volume>(<issue>3</issue>):<fpage>423</fpage>–<lpage>429</lpage>.</citation>
</ref>
<ref id="bibr30-0003319711416804">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lampl</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Frey</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygenation–utility in intensive therapy–part 1</article-title>. <source>Anasthesiol Intensivmed Notfallmed Schmerzther</source>. <year>2009</year>;<volume>44</volume>(<issue>9</issue>):<fpage>578</fpage>–<lpage>585</lpage>; <comment>quiz 586</comment>.
</citation>
</ref>
<ref id="bibr31-0003319711416804">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharkey</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Current indications for hyperbaric oxygen therapy</article-title>. <source>ADF Health</source>. <year>2000</year>;<volume>1</volume>(<issue>2</issue>):<fpage>64</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr32-0003319711416804">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vann</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>FK</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>RE</given-names>
</name>
</person-group>. <article-title>Decompression illness</article-title>. <source>Lancet</source>. <year>2011</year>;<volume>377</volume>(<issue>9760</issue>):<fpage>153</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr33-0003319711416804">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Waili</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Beale</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>BY</given-names>
</name>
<name>
<surname>Lucas</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen and malignancies: a potential role in radiotherapy, chemotherapy, tumor surgery and phototherapy</article-title>. <source>Med Sci Monit</source>. <year>2005</year>;<volume>11</volume>(<issue>9</issue>):<fpage>RA279</fpage>–<lpage>RA289</lpage>.</citation>
</ref>
<ref id="bibr34-0003319711416804">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cankar</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Finderle</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Jan</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>The effect of hyperbaric oxygenation on postradiation xerostomia and saliva in patients with head and neck tumours</article-title>. <source>Caries Res</source>. <year>2011</year>;<volume>45</volume>(<issue>2</issue>):<fpage>136</fpage>–<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr35-0003319711416804">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feldmeier</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Heimbach</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Davolt</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Court</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Stegmann</surname>
<given-names>BJ</given-names>
</name>
<name>
<surname>Sheffield</surname>
<given-names>PJ</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen an adjunctive treatment for delayed radiation injuries of the abdomen and pelvis</article-title>. <source>Undersea Hyperb Med</source>. <year>1996</year>;<volume>23</volume>(<issue>4</issue>):<fpage>205</fpage>–<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr36-0003319711416804">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marshall</surname>
<given-names>GT</given-names>
</name>
<name>
<surname>Thirlby</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Bredfeldt</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Hampson</surname>
<given-names>NB</given-names>
</name>
</person-group>. <article-title>Treatment of gastrointestinal radiation injury with hyperbaric oxygen</article-title>. <source>Undersea Hyperb Med</source>. <year>2007</year>;<volume>34</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr37-0003319711416804">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Widmark</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Flodgren</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Damber</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Hellsten</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cavallin-Ståhl</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>A systematic overview of radiation therapy effects in urinary bladder cancer</article-title>. <source>Acta Oncol</source>. <year>2003</year>;<volume>42</volume>(<issue>5-6</issue>):<fpage>567</fpage>–<lpage>581</lpage>.</citation>
</ref>
<ref id="bibr38-0003319711416804">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gottrup</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Oxygen in wound healing and infection</article-title>. <source>World J Surg</source>. <year>2004</year>;<volume>28</volume>(<issue>3</issue>):<fpage>312</fpage>–<lpage>315</lpage>.</citation>
</ref>
<ref id="bibr39-0003319711416804">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skiada</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Petrikkos</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Cutaneous zygomycosis</article-title>. <source>Clin Microbiol Infect</source>. <year>2009</year>;<volume>15</volume>(<issue>suppl 5</issue>):<fpage>41</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr40-0003319711416804">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geraci</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Pisello</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lupo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cajozzo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sciumè</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Modica</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Fournier’s gangrene: case report and review of recent literature</article-title>. <source>Ann Ital Chir</source>. <year>2004</year>;<volume>75</volume>(<issue>1</issue>):<fpage>97</fpage>–<lpage>106</lpage>.</citation>
</ref>
<ref id="bibr41-0003319711416804">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Passavanti</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>The use of the hyperbaric oxygenation therapy in urology</article-title>. <source>Arch Ital Urol Androl</source>. <year>2010</year>;<volume>82</volume>(<issue>4</issue>):<fpage>173</fpage>–<lpage>176</lpage>.</citation>
</ref>
<ref id="bibr42-0003319711416804">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buettner</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Wolkenhauer</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen therapy in the treatment of open fractures and crush injuries</article-title>. <source>Emerg Med Clin North Am</source>. <year>2007</year>;<volume>25</volume>(<issue>1</issue>):<fpage>177</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr43-0003319711416804">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palzur</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vlodavsky</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mulla</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Arieli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Feinsod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Soustiel</surname>
<given-names>JF</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen therapy for reduction of secondary brain damage in head injury: an animal model of brain contusion</article-title>. <source>J Neurotrauma</source>. <year>2004</year>;<volume>21</volume>(<issue>1</issue>):<fpage>41</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr44-0003319711416804">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Buettner</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Wolkenhauer</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen therapy in the treatment of open fractures and crush injuries</article-title>. <source>Emerg Med Clin North Am</source>. <year>2007</year>;<volume>25</volume>(<issue>1</issue>):<fpage>177</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr45-0003319711416804">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michalski</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Härtig</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hobohm</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Use of normobaric and hyperbaric oxygen in acute focal cerebral ischemia—a preclinical and clinical review</article-title>. <source>Acta Neurol Scand</source>. <year>2011</year>;<volume>123</volume>(<issue>2</issue>):<fpage>85</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr46-0003319711416804">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>JR</given-names>
</name>
</person-group>. <article-title>Update on autism: a review of 1300 reports published in 2008</article-title>. <source>Epilepsy Behav</source>. <year>2009</year>;<volume>16</volume>(<issue>4</issue>):<fpage>569</fpage>–<lpage>589</lpage>.</citation>
</ref>
<ref id="bibr47-0003319711416804">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanno</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nagata</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nonomura</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>New approaches in the treatment of hypertensive intracerebral hemorrhage</article-title>. <source>Stroke</source>. <year>1993</year>;<volume>24</volume>(<issue>suppl 12</issue>):<fpage>I96</fpage>–<lpage>I100</lpage>; <comment>discussion I107-I108</comment>.
</citation>
</ref>
<ref id="bibr48-0003319711416804">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kao</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Nañagas</surname>
<given-names>KA</given-names>
</name>
</person-group>. <article-title>Carbon monoxide poisoning</article-title>. <source>Med Clin North Am</source>. <year>2005</year>;<volume>89</volume>(<issue>6</issue>):<fpage>1161</fpage>–<lpage>1194</lpage>.</citation>
</ref>
<ref id="bibr49-0003319711416804">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kealey</surname>
<given-names>GP</given-names>
</name>
</person-group>. <article-title>Carbon monoxide toxicity</article-title>. <source>J Burn Care Res</source>. <year>2009</year>;<volume>30</volume>(<issue>1</issue>):<fpage>146</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr50-0003319711416804">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toon</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Maybauer</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Greenwood</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Maybauer</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Fraser</surname>
<given-names>JF</given-names>
</name>
</person-group>. <article-title>Management of acute smoke inhalation injury</article-title>. <source>Crit Care Resusc</source>. <year>2010</year>;<volume>12</volume>(<issue>1</issue>):<fpage>53</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr51-0003319711416804">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baroni</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Porro</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Faglia</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Hyperbaric oxygen in diabetic gangrene treatment</article-title>. <source>Diabetes Care</source>. <year>1987</year>;<volume>10</volume>(<issue>1</issue>):<fpage>81</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr52-0003319711416804">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oriani</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Meazza</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Favales</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pizzi</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Aldeghi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Faglia</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen therapy in diabetic gangrene</article-title>. <source>J Hyperb Med</source>. <year>1990</year>;<volume>5</volume>(<issue>2</issue>):<fpage>171</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr53-0003319711416804">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faglia</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Favales</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Aldeghi</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study</article-title>. <source>Diabetes Care</source>. <year>1996</year>;<volume>19</volume>(<issue>12</issue>):<fpage>1338</fpage>–<lpage>1343</lpage>.</citation>
</ref>
<ref id="bibr54-0003319711416804">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zamboni</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>HP</given-names>
</name>
<name>
<surname>Stephenson</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Pfeifer</surname>
<given-names>MA</given-names>
</name>
</person-group>. <article-title>Evaluation of hyperbaric oxygen for diabetic wounds: a prospective study</article-title>. <source>Undersea Hyperb Med</source>. <year>1997</year>;<volume>24</volume>(<issue>3</issue>):<fpage>175</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr55-0003319711416804">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jörneskog</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Naderi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lind</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Brismar</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers. Long-term follow-up</article-title>. <source>J Diabetes Complications</source>. <year>2002</year>;<volume>16</volume>(<issue>2</issue>):<fpage>153</fpage>–<lpage>158</lpage>.</citation>
</ref>
<ref id="bibr56-0003319711416804">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kessler</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bilbault</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ortéga</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study</article-title>. <source>Diabetes Care</source>. <year>2003</year>;<volume>26</volume>(<issue>8</issue>):<fpage>2378</fpage>–<lpage>2382</lpage>.</citation>
</ref>
<ref id="bibr57-0003319711416804">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abidia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Laden</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kuhan</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial</article-title>. <source>Eur J Vasc Endovasc Surg</source>. <year>2003</year>;<volume>25</volume>(<issue>6</issue>):<fpage>513</fpage>–<lpage>518</lpage>.</citation>
</ref>
<ref id="bibr58-0003319711416804">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duzgun</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Satir</surname>
<given-names>HZ</given-names>
</name>
<name>
<surname>Ozozan</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Saylam</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kulah</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Coskun</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers</article-title>. <source>J Foot Ankle Surg</source>. <year>2008</year>;<volume>47</volume>(<issue>6</issue>):<fpage>515</fpage>–<lpage>519</lpage>.</citation>
</ref>
<ref id="bibr59-0003319711416804">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyon</surname>
<given-names>KC</given-names>
</name>
</person-group>. <article-title>The case for evidence in wound care: investigating advanced treatment modalities in healing chronic diabetic lower extremity wounds</article-title>. <source>J Wound Ostomy Continence Nurs</source>. <year>2008</year>;<volume>35</volume>(<issue>6</issue>):<fpage>585</fpage>–<lpage>590</lpage>.</citation>
</ref>
<ref id="bibr60-0003319711416804">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaya</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aydin</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Altay</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Karapinar</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ozturk</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Karakuzu</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Can major amputation rates be decreased in diabetic foot ulcers with hyperbaric oxygen therapy?</article-title> <source>Int Orthop</source>. <year>2009</year>;<volume>33</volume>(<issue>2</issue>):<fpage>441</fpage>–<lpage>446</lpage>.</citation>
</ref>
<ref id="bibr61-0003319711416804">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Fong</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Juhn</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Treatment of diabetic foot infection with hyperbaric oxygen therapy</article-title>. <source>Foot Ankle Surg</source>. <year>2010</year>;<volume>16</volume>(<issue>2</issue>):<fpage>91</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr62-0003319711416804">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Löndahl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katzman</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hammarlund</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes</article-title>. <source>Diabetes Care</source>. <year>2010</year>;<volume>33</volume>(<issue>5</issue>):<fpage>998</fpage>–<lpage>1003</lpage>.</citation>
</ref>
<ref id="bibr63-0003319711416804">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kranke</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roeckl-Wiedmann</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Debus</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen therapy for chronic wounds</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2004;</year>;<fpage>CD004123</fpage>.</citation>
</ref>
<ref id="bibr64-0003319711416804">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boulton</surname>
<given-names>AJ</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen in the management of chronic diabetic foot ulcers</article-title>. <source>Curr Diab Rep</source>. <year>2010</year>;<volume>10</volume>(<issue>4</issue>):<fpage>255</fpage>–<lpage>256</lpage>.</citation>
</ref>
<ref id="bibr65-0003319711416804">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Marston</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Armstrong</surname>
<given-names>DG</given-names>
</name>
</person-group>. <article-title>Wound care: the role of advanced wound-healing technologies</article-title>. <source>J Am Podiatr Med Assoc</source>. <year>2010</year>;<volume>100</volume>(<issue>5</issue>):<fpage>385</fpage>–<lpage>394</lpage>.</citation>
</ref>
<ref id="bibr66-0003319711416804">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lipsky</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Berendt</surname>
<given-names>AR</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen therapy for diabetic foot wounds: has hope hurdled hype?</article-title> <source>Diabetes Care</source>. <year>2010</year>;<volume>33</volume>(<issue>5</issue>):<fpage>1143</fpage>–<lpage>1145</lpage>.</citation>
</ref>
<ref id="bibr67-0003319711416804">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Löndahl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fagher</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Katzman</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>What is the role of hyperbaric oxygen in the management of diabetic foot disease?</article-title> <source>Curr Diab Rep</source>. <year>2011</year>;<volume>11</volume>:<fpage>285</fpage>–<lpage>293</lpage>.</citation>
</ref>
<ref id="bibr68-0003319711416804">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author"><name><surname>Cianci</surname><given-names>P</given-names></name><name><surname>Petrone</surname><given-names>G</given-names></name><name><surname>Green</surname><given-names>B</given-names></name></person-group>. <article-title>Adjunctive hyperbaric oxygen in the salvage of the diabetic foot</article-title>. <source>Undersea and Hyperbaric Medical Society. Annual Scientific Meeting. San Diego</source>. <year>1991</year>.</citation>
</ref>
<ref id="bibr69-0003319711416804">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wattel</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mathieu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Coget</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Billard</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen therapy in chronic vascular wound management</article-title>. <source>Angiology</source>. <year>1990</year>;<volume>41</volume>(<issue>1</issue>):<fpage>59</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr70-0003319711416804">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doctor</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pandya</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Supe</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen therapy in diabetic foot</article-title>. <source>J Postgrad Med</source>. <year>1992</year>;<volume>38</volume>(<issue>1</issue>):<fpage>111</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr71-0003319711416804">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stone</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Cianci</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>The adjunctive role of hyperbaric oxygen therapy in the treatment of lower extremity wounds in patients with diabetes</article-title>. <source>Diabetes Spectrum</source>. <year>1997</year>;<volume>10</volume>(<issue>2</issue>):<fpage>118</fpage>–<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr72-0003319711416804">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faglia</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Favales</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Aldeghi</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Change in major amputation rate in a center dedicated to diabetic foot care during the 1980s: prognostic determinants for major amputation</article-title>. <source>J Diabetes Complications</source>. <year>1998</year>;<volume>12</volume>(<issue>2</issue>):<fpage>96</fpage>–<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr73-0003319711416804">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ong</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen therapy in the management of diabetic lower limb wounds</article-title>. <source>Singapore Med J</source>. <year>2008</year>;<volume>49</volume>(<issue>2</issue>):<fpage>105</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr74-0003319711416804">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gray</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ratliff</surname>
<given-names>CR</given-names>
</name>
</person-group>. <article-title>Is hyperbaric oxygen therapy effective for the management of chronic wounds?</article-title> <source>J Wound Ostomy Continence Nurs</source>. <year>2006</year>;<volume>33</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr75-0003319711416804">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunter</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Langemo</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hanson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen therapy for chronic wounds</article-title>. <source>Adv Skin Wound Care</source>. <year>2010</year>;<volume>23</volume>(<issue>8</issue>):<fpage>116</fpage>–<lpage>119</lpage>.</citation>
</ref>
<ref id="bibr76-0003319711416804">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katarina</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Magnus</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Per</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Jan</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Diabetic persons with foot ulcers and their perceptions of hyperbaric oxygen chamber therapy</article-title>. <source>J Clin Nurs</source>. <year>2009</year>;<volume>18</volume>(<issue>14</issue>):<fpage>1975</fpage>–<lpage>1985</lpage>.</citation>
</ref>
<ref id="bibr77-0003319711416804">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Yau</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>TK</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>KY</given-names>
</name>
</person-group>. <article-title>The efficacy of hyperbaric oxygen therapy in improving the quality of life in patients with problem wounds</article-title>. <source>J Nurs Res</source>. <year>2006</year>;<volume>14</volume>(<issue>3</issue>):<fpage>219</fpage>–<lpage>227</lpage>.</citation>
</ref>
<ref id="bibr78-0003319711416804">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Londahl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Landin-Olsson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katzman</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Complications-hyperbaric oxygen therapy improves health-related quality of life in patients with diabetes and chronic foot ulcer</article-title>. <source>Diabet Med</source>. <year>2011</year>;<volume>28</volume>(<issue>2</issue>):<fpage>186</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr79-0003319711416804">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aragón-Sánchez</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Treatment of diabetic foot osteomyelitis: a surgical critique</article-title>. <source>Int J Low Extrem Wounds</source>. <year>2010</year>;<volume>9</volume>(<issue>1</issue>):<fpage>37</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr80-0003319711416804">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berendt</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Bakker</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review of treatment</article-title>. <source>Diabetes Metab Res Rev</source>. <year>2008</year>;<volume>24</volume>(<issue>suppl 1</issue>):<fpage>S145</fpage>–<lpage>S161</lpage>.</citation>
</ref>
<ref id="bibr81-0003319711416804">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kardesoglu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Aparci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Uzun</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Hyperbaric oxygen therapy decreases QT dispersion in diabetic patients</article-title>. <source>Tohoku J Exp Med</source>. <year>2008</year>;<volume>215</volume>(<issue>1</issue>):<fpage>113</fpage>–<lpage>117</lpage>.</citation>
</ref>
<ref id="bibr82-0003319711416804">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Waili</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Beale</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Influences of hyperbaric oxygen on blood pressure, heart rate and blood glucose levels in patients with diabetes mellitus and hypertension</article-title>. <source>Arch Med Res</source>. <year>2006</year>;<volume>37</volume>(<issue>8</issue>):<fpage>991</fpage>–<lpage>997</lpage>.</citation>
</ref>
<ref id="bibr83-0003319711416804">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karadurmus</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sahin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tasci</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Potential benefits of hyperbaric oxygen therapy on atherosclerosis and glycaemic control in patients with diabetic foot</article-title>. <source>Endokrynol Pol</source>. <year>2010</year>;<volume>61</volume>(<issue>3</issue>):<fpage>275</fpage>–<lpage>279</lpage>.</citation>
</ref>
<ref id="bibr84-0003319711416804">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Nagatomo</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fujino</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Tsuda</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ishihara</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Hyperbaric oxygen exposure improves blood glucose level and muscle oxidative capacity in rats with type 2 diabetes</article-title>. <source>Diabetes Technol Ther</source>. <year>2010</year>;<volume>12</volume>(<issue>2</issue>):<fpage>125</fpage>–<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr85-0003319711416804">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsunami</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Morishima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mano</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yukawa</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Enhancement of glucose toxicity by hyperbaric oxygen exposure in diabetic rats</article-title>. <source>Tohoku J Exp Med</source>. <year>2008</year>;<volume>216</volume>(<issue>2</issue>):<fpage>127</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr86-0003319711416804">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zgonis</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Garbalosa</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Burns</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vidt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lowery</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>A retrospective study of patients with diabetes mellitus after partial foot amputation and hyperbaric oxygen treatment</article-title>. <source>J Foot Ankle Surg</source>. <year>2005</year>;<volume>44</volume>(<issue>4</issue>):<fpage>276</fpage>–<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr87-0003319711416804">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fife</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Buyukcakir</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Otto</surname>
<given-names>GH</given-names>
</name>
<etal/>
</person-group>. <article-title>The predictive value of transcutaneous oxygen tension measurement in diabetic lower extremity ulcers treated with hyperbaric oxygen therapy: a retrospective analysis of 1,144 patients</article-title>. <source>Wound Repair Regen</source>. <year>2002</year>;<volume>10</volume>(<issue>4</issue>):<fpage>198</fpage>–<lpage>207</lpage>.</citation>
</ref>
<ref id="bibr88-0003319711416804">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fife</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Buyukcakir</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Otto</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sheffield</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Love</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Warriner</surname>
<given-names>R 3rd</given-names>
</name>
</person-group>. <article-title>Factors influencing the outcome of lower-extremity diabetic ulcers treated with hyperbaric oxygen therapy</article-title>. <source>Wound Repair Regen</source>. <year>2007</year>;<volume>15</volume>(<issue>3</issue>):<fpage>322</fpage>–<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr89-0003319711416804">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berendt</surname>
<given-names>AR</given-names>
</name>
</person-group>. <article-title>Counterpoint: hyperbaric oxygen for diabetic foot wounds is not effective</article-title>. <source>Clin Infect Dis</source>. <year>2006</year>;<volume>43</volume>(<issue>2</issue>):<fpage>193</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr90-0003319711416804">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heyneman</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Lawless-Liday</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Using hyperbaric oxygen to treat diabetic foot ulcers: safety and effectiveness</article-title>. <source>Crit Care Nurse</source>. <year>2002</year>;<volume>22</volume>(<issue>6</issue>):<fpage>52</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr91-0003319711416804">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carls</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Driver</surname>
<given-names>VR</given-names>
</name>
<etal/>
</person-group>. <article-title>The economic value of specialized lower-extremity medical care by podiatric physicians in the treatment of diabetic foot ulcers</article-title>. <source>J Am Podiatr Med Assoc</source>. <year>2011</year>;<volume>101</volume>(<issue>2</issue>):<fpage>93</fpage>–<lpage>115</lpage>.</citation>
</ref>
<ref id="bibr92-0003319711416804">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McMillan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Glover</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>The clinical and economic potential of hyperbaric oxygen therapy in the treatment of diabetic ulceration and other conditions</article-title>. <source>Low Extrem Wounds</source>. <year>2007</year>;<volume>6</volume>(<issue>3</issue>):<fpage>130</fpage>–<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr93-0003319711416804">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Counte</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Gillespie</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Cost-effectiveness of adjunctive hyperbaric oxygen in the treatment of diabetic ulcers</article-title>. <source>Int J Technol Assess Health Care</source>. <year>2003</year>;<volume>19</volume>(<issue>4</issue>):<fpage>731</fpage>–<lpage>737</lpage>.</citation>
</ref>
<ref id="bibr94-0003319711416804">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chow</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lemos</surname>
<given-names>EV</given-names>
</name>
<name>
<surname>Einarson</surname>
<given-names>TR</given-names>
</name>
</person-group>. <article-title>Management and prevention of diabetic foot ulcers and infections: a health economic review</article-title>. <source>Pharmacoeconomics</source>. <year>2008</year>;<volume>26</volume>(<issue>12</issue>):<fpage>1019</fpage>–<lpage>1035</lpage>.</citation>
</ref>
<ref id="bibr95-0003319711416804">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chuck</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Hailey</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>DC</given-names>
</name>
</person-group>. <article-title>Cost-effectiveness and budget impact of adjunctive hyperbaric oxygen therapy for diabetic foot ulcers</article-title>. <source>Int J Technol Assess Health Care</source>. <year>2008</year>;<volume>24</volume>(<issue>2</issue>):<fpage>178</fpage>–<lpage>183</lpage>.</citation>
</ref>
<ref id="bibr96-0003319711416804">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feldmeier</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Hopf</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Warriner</surname>
<given-names>RA 3rd</given-names>
</name>
<name>
<surname>Fife</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Gesell</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>UHMS position statement: topical oxygen for chronic wounds</article-title>. <source>Undersea Hyperb Med</source>. <year>2005</year>;<volume>32</volume>(<issue>3</issue>):<fpage>157</fpage>–<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr97-0003319711416804">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heng</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Harker</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bardakjian</surname>
<given-names>VB</given-names>
</name>
<name>
<surname>Ayvazian</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Enhanced healing and cost-effectiveness of low-pressure oxygen therapy in healing necrotic wounds: a feasibility study of technology transfer</article-title>. <source>Ostomy Wound Manage</source>. <year>2000</year>;<volume>46</volume>(<issue>3</issue>):<fpage>52</fpage>–<lpage>60, 62</lpage>.</citation>
</ref>
<ref id="bibr98-0003319711416804">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Landau</surname>
<given-names>Z</given-names>
</name>
</person-group>. <article-title>Topical hyperbaric oxygen and low energy laser for the treatment of diabetic foot ulcers</article-title>. <source>Arch Orthop Trauma Surg</source>. <year>1998</year>;<volume>117</volume>(<issue>3</issue>):<fpage>156</fpage>–<lpage>158</lpage>.</citation>
</ref>
<ref id="bibr99-0003319711416804">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Landau</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Sommer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>EB</given-names>
</name>
</person-group>. <article-title>Topical hyperbaric oxygen and low-energy laser for the treatment of chronic ulcers</article-title>. <source>Eur J Intern Med</source>. <year>2006</year>;<volume>17</volume>(<issue>4</issue>):<fpage>272</fpage>–<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr100-0003319711416804">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Landau</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Schattner</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Topical hyperbaric oxygen and low energy laser therapy for chronic diabetic foot ulcers resistant to conventional treatment</article-title>. <source>Yale J Biol Med</source>. <year>2001</year>;<volume>74</volume>(<issue>2</issue>):<fpage>95</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr101-0003319711416804">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leslie</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Sapico</surname>
<given-names>FL</given-names>
</name>
<name>
<surname>Ginunas</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Adkins</surname>
<given-names>RH</given-names>
</name>
</person-group>. <article-title>Randomized controlled trial of topical hyperbaric oxygen for treatment of diabetic foot ulcers</article-title>. <source>Diabetes Care</source>. <year>1988</year>;<volume>11</volume>(<issue>2</issue>):<fpage>111</fpage>–<lpage>115</lpage>.</citation>
</ref>
<ref id="bibr102-0003319711416804">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heng</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Harker</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Csathy</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Angiogenesis in necrotic ulcers treated with hyperbaric oxygen</article-title>. <source>Ostomy Wound Manage</source>. <year>2000</year>;<volume>46</volume>(<issue>9</issue>):<fpage>18</fpage>–<lpage>28</lpage>, <fpage>30</fpage>–<lpage>32</lpage>.
</citation>
</ref>
<ref id="bibr103-0003319711416804">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mathieu</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mani</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>A review of the clinical significance of tissue hypoxia measurements in lower extremity wound management</article-title>. <source>Int J Low Extrem Wounds</source>. <year>2007</year>;<volume>6</volume>(<issue>4</issue>):<fpage>273</fpage>.</citation>
</ref>
<ref id="bibr104-0003319711416804">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brismar</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fagrell</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ostergren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jorneskog</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Transcutaneous oxygen tension and toe blood pressure as predictors for outcome of diabetic foot ulcers</article-title>. <source>Diabetes care</source>. <year>1999</year>;<volume>22</volume>(<issue>1</issue>):<fpage>147</fpage>–<lpage>151</lpage>.</citation>
</ref>
<ref id="bibr105-0003319711416804">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Löndahl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Katzman</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hammarlund</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Landin-Olsson</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Relationship between ulcer healing after hyperbaric oxygen therapy and transcutaneous oximetry, toe blood pressure and ankle-brachial index in patients with diabetes and chronic foot ulcers</article-title>. <source>Diabetologia</source>. <year>2011</year>;<volume>54</volume>(<issue>1</issue>):<fpage>65</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr106-0003319711416804">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grolman</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Wilkerson</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Allinson</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zatina</surname>
<given-names>MA</given-names>
</name>
</person-group>. <article-title>Transcutaneous oxygen measurements predict a beneficial response to hyperbaric oxygen therapy in patients with nonhealing wounds and critical limb ischemia</article-title>. <source>Am Surg</source>. <year>2001</year>;<volume>67</volume>(<issue>11</issue>):<fpage>1072</fpage>–<lpage>1079</lpage>; <comment>discussion 1080</comment>.
</citation>
</ref>
<ref id="bibr107-0003319711416804">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oubre</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Toner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kalns</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Retrospective study of factors affecting non-healing of wounds during hyperbaric oxygen therapy</article-title>. <source>J Wound Care</source>. <year>2007</year>;<volume>16</volume>(<issue>6</issue>):<fpage>245</fpage>–<lpage>250</lpage>.</citation>
</ref>
<ref id="bibr108-0003319711416804">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fife</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Smart</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Sheffield</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Hopf</surname>
<given-names>HW</given-names>
</name>
<name>
<surname>Hawkins</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Transcutaneous oximetry in clinical practice: consensus statements from an expert panel based on evidence</article-title>. <source>Undersea Hyperb Med</source>. <year>2009</year>;<volume>36</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr109-0003319711416804">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cicco</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Giorgino</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cicco</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Wound healing in diabetes: hemorheological and microcirculatory aspects</article-title>. <source>Adv Exp Med Biol</source>. <year>2011</year>;<volume>915</volume>(<issue>6</issue>):<fpage>263</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr110-0003319711416804">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flegg</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Byrne</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>McElwain</surname>
<given-names>DL</given-names>
</name>
</person-group>. <article-title>Mathematical model of hyperbaric oxygen therapy applied to chronic diabetic wounds</article-title>. <source>Bull Math Biol</source>. <year>2010</year>;<volume>72</volume>(<issue>7</issue>):<fpage>1867</fpage>–<lpage>1891</lpage>.</citation>
</ref>
<ref id="bibr111-0003319711416804">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cianci</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Advances in the treatment of the diabetic foot: is there a role for adjunctive hyperbaric oxygen therapy?</article-title> <source>Wound Rep Reg</source>. <year>2004</year>;<volume>12</volume>(<issue>1</issue>):<fpage>2</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr112-0003319711416804">
<label>112</label>
<citation citation-type="book">
<article-title>Recommendations of the jury. Hyperbaric medicine. Hyperbaric oxygen in the management of foot lesions in diabetic patients</article-title>. <source>4th European Consensus Conference on Hyperbaric Medicine</source>. <year>1998</year>; <day>4-5</day> <month>Dec</month>: <publisher-name>Bloomsbury</publisher-name>, <publisher-loc>London, United Kingdom</publisher-loc>.
</citation>
</ref>
<ref id="bibr113-0003319711416804">
<label>113</label>
<citation citation-type="journal">
<collab collab-type="author">American Diabetes Association: consensus development conference on diabetic foot wound care (consensus statement)</collab>.<source>Diabetes Care</source>. <year>1999</year>;<volume>22</volume>(<issue>2</issue>):<fpage>1354</fpage>–<lpage>1360</lpage>.</citation>
</ref>
<ref id="bibr114-0003319711416804">
<label>114</label>
<citation citation-type="journal">
<person-group person-group-type="author"><name><surname>Shuren</surname><given-names>J</given-names></name><name><surname>Dei Cas</surname><given-names>R</given-names></name><name><surname>Kucken</surname><given-names>L</given-names></name><name><surname>Tillman</surname><given-names>K</given-names></name></person-group>. <article-title>Coverage decision memorandum for hyperbaric oxygen therapy in the treatment of hypoxic wounds and diabetic wounds of the lower extremities</article-title>. <source>CMS</source>. <comment>Administrative File: CAG-00060N, 30 Aug.</comment> <year>2002</year>.
</citation>
</ref>
<ref id="bibr115-0003319711416804">
<label>115</label>
<citation citation-type="web">
<collab collab-type="author">BlueCross BlueShield of Tennessee Medical Policy Manual</collab>. <ext-link ext-link-type="uri" xlink:href="http://www.bcbst.com/mpmanual/!ssl!/webhelp/mpmprov.htm#Hyperbaric_Oxygen_Pressurization__Therapy_HBO2.htm">http://www.bcbst.com/mpmanual/!ssl!/webhelp/mpmprov.htm#Hyperbaric_Oxygen_Pressurization__Therapy_HBO2.htm</ext-link>. <comment>Accessed June 6, 2011</comment>.
</citation>
</ref>
<ref id="bibr116-0003319711416804">
<label>116</label>
<citation citation-type="web">
<collab collab-type="author">Australian Medicare Services Advisory Committee (MSAC)</collab>. <source>Hyperbaric Oxygen Therapy</source>. <comment>MSAC applications</comment>;<volume>2000</volume>:<fpage>1018</fpage>–<lpage>1020</lpage>. <ext-link ext-link-type="uri" xlink:href="http://www.msac.gov.au/internet/msac/publishing.nsf/Content/app1018-1020-1">http://www.msac.gov.au/internet/msac/publishing.nsf/Content/app1018-1020-1</ext-link>
</citation>
</ref>
<ref id="bibr117-0003319711416804">
<label>117</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Räkel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Huot</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ekoé</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Canadian Diabetes Association Technical Review: the diabetic foot and hyperbaric oxygen therapy</article-title>. <source>Can J Diabetes</source>. <year>2006</year>;<volume>30</volume>(<issue>2</issue>):<fpage>411</fpage>–<lpage>421</lpage>.</citation>
</ref>
<ref id="bibr118-0003319711416804">
<label>118</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steed</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Attinger</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Colaizzi</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Guidelines for the treatment of diabetic ulcers. Wound Healing Society</article-title>. <source>Wound Rep Reg</source>. <year>2006</year>;<volume>14</volume>(<issue>1</issue>):<fpage>680</fpage>–<lpage>692</lpage>.</citation>
</ref>
<ref id="bibr119-0003319711416804">
<label>119</label>
<citation citation-type="web">
<collab collab-type="author">Oxford and CMS policies</collab>. <article-title>Hyperbaric Oxygen Therapy for Medicare Plans</article-title>. <year>2009</year>; <source>Policy #: REHAB 018.7 T2</source>. <ext-link ext-link-type="uri" xlink:href="https://www.oxhp.com/secure/policy/hyperbaric_oxygen_oma_1209.html">https://www.oxhp.com/secure/policy/hyperbaric_oxygen_oma_1209.html</ext-link>. <comment>Accessed May 8, 2011</comment>.
</citation>
</ref>
<ref id="bibr120-0003319711416804">
<label>120</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snyder</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Kisner</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Warriner</surname>
<given-names>RA</given-names>
<suffix>III</suffix>
</name>
<name>
<surname>Lavery</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Hanft</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Sheehan</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Consensus recommendations on advancing the standard of care for treating neuropathic foot ulcers in patients with diabetes</article-title>. <source>Ostomy Wound Manage</source>. <year>2010</year>;<volume>56</volume>(<issue>suppl 4</issue>):<fpage>S1</fpage>–<lpage>S24</lpage>.</citation>
</ref>
<ref id="bibr121-0003319711416804">
<label>121</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fife</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Hopf</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Discussion. Hyperbaric oxygen: its mechanisms and efficacy</article-title>. <source>Plast Reconstr Surg</source>. <year>2011</year>;<volume>127</volume>(<issue>suppl 1</issue>):<fpage>142S</fpage>–<lpage>143S</lpage>.</citation>
</ref>
<ref id="bibr122-0003319711416804">
<label>122</label>
<citation citation-type="other">
<person-group person-group-type="author"><name><surname>Löndahl</surname><given-names>M</given-names></name><name><surname>Katzman</surname><given-names>P</given-names></name><name><surname>Hammarlund</surname><given-names>C</given-names></name><name><surname>Nilsson</surname><given-names>A</given-names></name><name><surname>Landin-Olsson</surname><given-names>M</given-names></name></person-group>. <article-title>Improved survival in patients with diabetes and chronic foot ulcers after hyperbaric oxygen therapy. Outcome of a randomised double-blind placebo controlled study</article-title>. <comment>(abstract) Diabetic foot study group</comment>. <year>2010</year>.
</citation>
</ref>
<ref id="bibr123-0003319711416804">
<label>123</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Efrati</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gall</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bergan</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Hyperbaric oxygen, oxidative stress, NO bioavailability and ulcer oxygenation in diabetic patients</article-title>. <source>Undersea Hyperb Med</source>. <year>2009</year>;<volume>36</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr124-0003319711416804">
<label>124</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chikenji</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Therapeutic outcome of hyperbaric oxygen and basic fibroblast growth factor on intractable skin ulcer in legs: preliminary report</article-title>. <source>Plast Reconstr Surg</source>. <year>2006</year>;<volume>117</volume>(<issue>2</issue>):<fpage>646</fpage>–<lpage>651</lpage>.<comment>discussion 652-653</comment>
</citation>
</ref>
<ref id="bibr125-0003319711416804">
<label>125</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Svehlík</surname>
<given-names>J</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Zábavníková</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Guzanin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Svehlíková</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Svehlík</surname>
<given-names>J</given-names>
<suffix>Sr</suffix>
</name>
</person-group>. <article-title>Hyperbaric oxygenotherapy as a possible means of preventing ischemic changes in skin grafts used for soft tissue defect closure</article-title>. <source>Acta Chir Plast</source>. <year>2007</year>;<volume>49</volume>(<issue>2</issue>):<fpage>31</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr126-0003319711416804">
<label>126</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Efficacy of hyperbaric oxygen on survival of random pattern skin flap in diabetic rats</article-title>. <source>Undersea Hyperb Med</source>. <year>2007</year>;<volume>34</volume>(<issue>5</issue>):<fpage>335</fpage>–<lpage>339</lpage>.</citation>
</ref>
<ref id="bibr127-0003319711416804">
<label>127</label>
<citation citation-type="other">
<collab collab-type="author">Working group 4 of the COST action B14</collab>. <article-title>Evaluation of hyperbaric oxygen therapy in the treatment of diabetic foot lesion. A randomised controlled prospective study</article-title>. <year>2004</year>.
</citation>
</ref>
<ref id="bibr128-0003319711416804">
<label>128</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Reilly</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Linden</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fedorko</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>A prospective, double-blind, randomized, controlled clinical trial comparing standard wound care with adjunctive hyperbaric oxygen therapy (HBOT) to standard wound care only for the treatment of chronic, non-healing ulcers of the lower limb in patients with diabetes mellitus: a study protocol</article-title>. <source>Trials</source>. <year>2011</year>;<volume>12</volume>:<fpage>69</fpage>.</citation>
</ref>
<ref id="bibr129-0003319711416804">
<label>129</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papanas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Maltezos</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Edmonds</surname>
<given-names>M St</given-names>
</name>
</person-group>. <article-title>Vincent declaration after 15 years or who cleft the devil’s foot?</article-title> <source>Vasa</source>. <year>2006</year>;<volume>35</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr130-0003319711416804">
<label>130</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Papanas</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lazarides</surname>
<given-names>MK</given-names>
</name>
</person-group>. <article-title>Diabetic foot amputations in Greece: where do we go from here?</article-title> <source>Int J Low Extrem Wounds</source>. <year>2011</year>;<volume>10</volume>(<issue>1</issue>):<fpage>4</fpage>–<lpage>5</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>